News

View

Sort By

Oct 24, 2017

Alector and AbbVie Announce Collaboration to Advance a Novel Class of Immune Therapies for Patients with Alzheimer's Disease

Oct 24, 2017

Acutus Medical® Receives FDA Clearance for Advanced Cardiac Mapping Technology for Complex Arrhythmias

Oct 24, 2017

NeuroPace Closes $74 Million Equity Funding to Accelerate Patient Access to the World's First Brain-Responsive Neurostimulation System to Treat Epilepsy

Oct 24, 2017

Synlogic Receives Orphan Drug Designation for SYNB1618, a Synthetic BioticTM Medicine for the Treatment of Phenylketonuria

Oct 23, 2017

Intercept Announces Positive Results from Phase 2 AESOP Trial Evaluating OCA for the Treatment of Patients with Primary Sclerosing Cholangitis at The Liver Meeting® 2017

Oct 23, 2017

Sébastien Desprez Joins Adaptimmune as Vice President of Communications and Investor Relations

Oct 23, 2017

SI-BONE's New iFuse-NavigationTM Set* and iFuse-3DTM Fenestrated SI Joint Fusion Implant to be Featured at the 2017 North American Spine Society Annual Meeting

Oct 23, 2017

Alpine Immune Sciences and Kite Extend Research Term of Collaboration to Create Next-Generation CAR-T and TCRs

Oct 18, 2017

Corvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

Oct 18, 2017

Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of Larotrectinib Dataset

Oct 17, 2017

Invitae data shows increased diagnosis rates with custom NGS technique allowing simultaneous genetic sequencing and copy number variant detection

Oct 17, 2017

Cyrus Bio Leads Computational Protein Engineering Panel

Oct 17, 2017

Xenon Pharmaceuticals Announces Initiation of XEN1101 Phase 1 Clinical Trial

Oct 16, 2017

Aeglea BioTherapeutics Announces Clinical Collaboration with Merck to Evaluate the Combination of Aeglea's AEB1102 (pegzilarginase) with Merck's KEYTRUDA® (pembrolizumab) for the Treatment of Small Cell Lung Cancer

Oct 16, 2017

Alpine Immune Sciences Announces Upcoming Scientific Presentations

Oct 16, 2017

Sierra Oncology to Report Chk1 Inhibitor SRA737 Preclinical Data at AACR-NCI-EORTC 2017

Oct 12, 2017

Pieris Pharmaceuticals Appoints Ingmar Bruns, M.D., Ph.D., As Vice President Of Clinical Development

Oct 11, 2017

Lupin Acquires Symbiomix Therapeutics LLC

Oct 10, 2017

Aerpio Pharmaceuticals Announces Appointment of Stephen Hoffman, M.D., Ph.D., as Chief Executive Officer and to the Board of Directors and the Transition of Joseph H. Gardner, Ph.D., to President and Founder

Oct 10, 2017

ObsEva SA Announces $60.0 Million Private Placement with Existing and New Investors

Oct 10, 2017

Rhythm Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 10, 2017

Synlogic Strengthens Leadership Team with Appointment of Chief Operating Officer and Chief Human Resources Officer

Oct 9, 2017

ARMO BioSciences Appoints Immuno-Oncology Industry Veteran Joseph Leveque, M.D., as Chief Medical Officer

Oct 9, 2017

Arsanis Presents Phase 1 and Preclinical Pharmacokinetic Data on Lead Product Candidate, ASN100, at IDWeek™ 2017

Oct 9, 2017

SI-BONE, Inc. Announces Utah's Public Employees Health Plan (PEHP) Establishes Coverage for the iFuse ProcedureTM for Minimally Invasive SI Joint Fusion

Oct 5, 2017

Glaukos iStent® Products to be Showcased at 2017 European Society of Cataract and Refractive Surgery

Oct 5, 2017

Invitae's new framework for classifying genetic variants aims to improve consistency of genetic test results industry-wide

Oct 4, 2017

Arsanis Announces Appointments of Chip Clark and David McGirr to Board of Directors and Promotion of Michael Gray to Chief Operating Officer and Chief Financial Officer

Oct 4, 2017

Samsung and TigerText Collaborate to Transform Healthcare Communications for Clinicians

Oct 3, 2017

Audentes Therapeutics Announces MHRA Approval of Clinical Trial Authorisation Application for AT132 to Treat X-Linked Myotubular Myopathy

Oct 2, 2017

Pieris Pharmaceuticals Announces Dosing Of First Patient In Phase I Trial For Fully Proprietary Lead Io Program, Prs-343

Oct 2, 2017

Dimension Board Determines That Ultragenyx's Unsolicited Proposal To Acquire Dimension For $6.00 Per Share Constitutes A "Superior Proposal"

Sep 28, 2017

Nabriva Therapeutics to Present Lefamulin Data at ID Week 2017

Sep 28, 2017

Tricida Initiates Phase 3 Study of TRC101 for the Treatment of Metabolic Acidosis Associated With Chronic Kidney Disease

Sep 27, 2017

Audentes Therapeutics Announces Rare Pediatric Disease and Fast Track Designations for AT132 for the Treatment of X-Linked Myotubular Myopathy

Sep 27, 2017

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

Sep 27, 2017

Loxo Oncology Announces Details of LOXO-292 Abstract to be Presented as Late-Breaking Presentation at the IASLC 18th World Conference on Lung Cancer

Sep 27, 2017

KaNDy Therapeutics Launched to Focus on a Breakthrough New Product in Women's Health

Sep 27, 2017

NeRRe Therapeutics appoints Andrew Kay as Chairman of the Board

Sep 27, 2017

KaNDy Therapeutics launched to advance a breakthrough treatment in Women's Health

Sep 27, 2017

Verona Pharma Reports Positive Top-Line Data from U.S. Pharmacokinetic Trial Demonstrating Nebulized RPL554 Delivers Optimal Clinical Dose to Patients

Sep 26, 2017

OrbiMed Invests $42.5mm in ViviMed

Sep 26, 2017

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

Sep 26, 2017

Ascendis Pharma A/S Announces Dosing of Subjects in Phase 1 Trial of TransCon PTH

Sep 26, 2017

Intellia Therapeutics Demonstrates Sustained and Durable Genome Editing with CRISPR/Cas9 in One-Year Animal Study

Sep 26, 2017

CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions

Sep 25, 2017

In a First, Pfizer Spins Out Biotech Firm with $103 Million in Funding

Sep 25, 2017

Amarin and HLS Therapeutics Announce Agreement to Commercialize Vascepa® in Canada

Sep 25, 2017

Intercept Statement Regarding Ocaliva® (obeticholic acid) Safety and Dosing in Primary Biliary Cholangitis (PBC) Patients

Sep 25, 2017

SI-BONE, Inc. Announces Publication of iMIA – a 2nd Multicenter Randomized Controlled Trial of the iFuse Implant System® vs Conservative Care

Sep 25, 2017

SpringWorks Therapeutics Launches with $103M in Series A Funding and Rights to Four Clinical Programs

Sep 25, 2017

Pfizer launches upstart with $103M, phase 3-ready meds

Sep 25, 2017

Pfizer spends billions to develop new drugs. It's not satisfied. So it's launching a startup

Sep 25, 2017

SpringWorks Spins Out of Pfizer With $103M to Give Shelved Drugs New Life

Sep 25, 2017

In A First, Pfizer Spins Out Biotech Firm With $103 Million In Funding

Sep 21, 2017

ViewRay MRIdian to be Featured in 21 Presentations from Seven Leading Centers at ASTRO

Sep 21, 2017

Audentes Therapeutics Announces Dosing of First Patient in ASPIRO, a Phase 1/2 Clinical Trial of AT132 for the Treatment of X-Linked Myotubular Myopathy

Sep 20, 2017

Inspire Medical Systems' Inspire Therapy for Reducing Obstructive Sleep Apnea Demonstrates Long-Term Safety and Sustained Benefit Following 5- Years of Treatment

Sep 20, 2017

Alpine Immune Sciences Announces Poster Presentation at 2017 ACR/ARHP Annual Meeting

Sep 20, 2017

Arvinas Appoints Dr. John Houston as President and Chief Executive Officer

Sep 19, 2017

Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a �Superior Proposal�

Sep 19, 2017

Nabriva Therapeutics Announces Pricing of Public Offering of Ordinary Shares of Approximately $80 Million

Sep 19, 2017

Graybug Vision Initiates Phase 1/2 Trial of GB-102 for Wet Age-related Macular Degeneration

Sep 19, 2017

Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter's option to purchase additional shares

Sep 18, 2017

Principia Biopharma Presents Late-Breaking Interim Phase 2 Data of PRN1008 in Pemphigus at European Academy of Dermatology and Venereology Meeting

Sep 18, 2017

Sonendo® announces growth investment from General Atlantic

Sep 18, 2017

FDA Approves Symbiomix Therapeutics' Solosec™ (secnidazole) Oral Granules for the Treatment of Bacterial Vaginosis in Adult Women

Sep 18, 2017

Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx

Sep 18, 2017

Nabriva Therapeutics Announces Proposed Public Offering of Ordinary Shares

Sep 18, 2017

Nabriva Therapeutics Announces Positive Topline Results from Global, Phase 3 Clinical Trial Evaluating IV and Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia

Sep 15, 2017

Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Sep 14, 2017

Glaukos to Outline Growth Strategy at Investor Day

Sep 14, 2017

Marinus Pharmaceuticals Announces Public Offering of Common Stock

Sep 14, 2017

Sierra Oncology to Host KOL Call with Dr. Thomas Helleday presenting """"DNA Damage Response (DDR) Targets Beyond PARP""""

Sep 13, 2017

Affimed Appoints Dr. Wolfgang Fischer as Chief Operating Officer

Sep 13, 2017

Otonomy Provides Business and Financial Update

Sep 13, 2017

Invitae Highlighting New Research, Expanded Suite of Services at National Society of Genetic Counselors (NSGC) 36th Annual Conference

Sep 13, 2017

Loxo Oncology Announces Initial LOXO-292 Clinical Data to be Presented as Late-Breaking Presentation at the IASLC 18th World Conference on Lung Cancer

Sep 12, 2017

Cerapedics Announces Publication of Two-Year IDE Study Follow-Up on i-FACTOR™ Bone Graft in the Cervical Spine 

Sep 11, 2017

ObsEva SA Announces Presentation Related to its PGF2a Receptor Antagonist at ACCP 2017 Annual Meeting

Sep 11, 2017

Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for Ganaxolone

Sep 9, 2017

ARMO BioSciences's Phase 1b Trials Demonstrate Continued Promising Response Rates and Survival in Patients with Advanced Pancreatic Cancer, NSCLC, and RCC

Sep 8, 2017

Singulex Receives New, Broad Patent for Digital Detection Of Cardiac Troponin-I Or Cardiac Troponin-T For Coronary Artery Disease Rule-Out

Sep 8, 2017

Arsanis Presents Preclinical Data on Lead Product Candidate, ASN100, at the “2017 ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance”

Sep 7, 2017

GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO

Sep 7, 2017

Summary ToggleSynlogic Presents New Preclinical Data at International Congress of Inborn Errors of Metabolism

Sep 7, 2017

Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®)

Sep 6, 2017

Symbiomix Therapeutics Announces Publication of Pivotal Phase 3 Data for Investigational Solosec™ for the Treatment of Bacterial Vaginosis

Sep 6, 2017

Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 Deficiency

Sep 6, 2017

ObsEva SA Announces the Completion of Patient Recruitment in the IMPLANT2 Phase 3 Clinical Trial in Assisted Reproductive Technology Ahead of Schedule

Sep 5, 2017

OrbiMed Launches $551 Million Asia Private Equity Fund

Sep 5, 2017

Ascendis Pharma A/S Announces Presentations on Rare Disease Endocrinology Pipeline at Upcoming Medical Conferences

Sep 5, 2017

ReViral initiates Phase 2a study of RV521 for treatment of Respiratory Syncytial Virus

Aug 31, 2017

Clementia Announces Data Presentations at Upcoming Medical Conferences in September

Aug 31, 2017

Dimension Therapeutics Commences Patient Dosing in Global, Multi-Center Phase 1/2 Clinical Trial of DTX301 in Ornithine Transcarbamylase (OTC) Deficiency

Aug 31, 2017

Nabriva Therapeutics Announces Resignation of Elyse Seltzer, M.D.

Aug 30, 2017

Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX™ in Patients with Ménière's Disease

Aug 30, 2017

Adaptimmune to Present at Upcoming CAR-TCR Summit; CEO James Noble to be a Keynote Speaker

Aug 29, 2017

ARMO BioSciences Raises $67 Million in a Series C-1 Financing

Aug 28, 2017

Synlogic Completes Merger with Mirna Therapeutics

Aug 25, 2017

REGENXBIO to Acquire Dimension Therapeutics

Aug 23, 2017

SI-BONE, Inc. Announces Highmark, Inc., 4th Largest Blue Cross Blue Shield Plan and 10th Largest U.S. Commercial Payor, Establishes Positive Coverage Policy for Minimally Invasive Sacroiliac Joint Fusion Exclusively for the iFuse Implant System®

Aug 22, 2017

Avitide, Inc., Receives Iso 9001:2015 Certification For Its Affinity Resin Manufacturing Facility

Aug 21, 2017

Clementia Announces Closing of Over-Allotment Option in its Initial Public Offering

Aug 18, 2017

Ascendis Pharma A/S Reports Second Quarter 2017 Financial Results

Aug 17, 2017

Roka Bioscience, Inc. Agrees to Sell its Assets to Subsidiary of Institute for Environmental Health, Inc.

Aug 15, 2017

ObsEva Reports Second Quarter 2017 Financial Results and Provides Business Update

Aug 15, 2017

Sierra Oncology Establishes Distinguished DNA Damage Response Advisory Committee

Aug 14, 2017

Aerpio Reports Second Quarter 2017 Financial Results

Aug 10, 2017

Pieris Pharmaceuticals Appoints Allan Reine, M.D., as Chief Financial Officer

Aug 10, 2017

Audentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update

Aug 10, 2017

Symbiomix Therapeutics Presents New Data on Solosec™

Aug 10, 2017

Sierra Oncology Reports Second Quarter 2017 Results

Aug 9, 2017

Pieris Pharmaceuticals Reports Financial Results for the Second Quarter Ended June 30, 2017 and Provides Corporate Update

Aug 9, 2017

Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results

Aug 9, 2017

SI-BONE, Inc. Announces Publication of a Level I Study Demonstrating Strong Clinical Prediction for the Diagnosis of SI Joint Dysfunction

Aug 8, 2017

Aerpio Pharmaceuticals Commences Trading on the OTCQB® Market

Aug 8, 2017

Dimension Therapeutics Reports Second Quarter 2017 Financial Results And Provides Corporate Update

Aug 8, 2017

Loxo Oncology Announces Second Quarter 2017 Financial Results

Aug 8, 2017

Verona Pharma plc Interim Results for the Six Months Ended June 30, 2017 and Clinical Development Update

Aug 7, 2017

ViewRay Reports Second Quarter 2017 Financial Results

Aug 7, 2017

Invitae Reports Second Quarter 2017 Results

Aug 7, 2017

Nabriva Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights

Aug 3, 2017

Early Clinical Experience with ViewRay's MRIdian Linac Presented at Leading Medical Physics Meeting

Aug 3, 2017

Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate Update

Aug 3, 2017

Adaptimmune Reports Second Quarter 2017 Financial Results

Aug 3, 2017

Corvus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update

Aug 3, 2017

Invitae Acquiring Good Start Genetics and CombiMatrix, Adding Comprehensive Reproductive Health Capabilities to Serve Every Stage of Life

Aug 3, 2017

Xenon Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update

Aug 2, 2017

Amoy Diagnostics Co., Ltd. Starts IPO on Shenzhen Stock Exchange

Aug 2, 2017

Glaukos Corporation Announces Second Quarter 2017 Financial Results

Aug 2, 2017

SI-BONE, Inc. Announces Publication of iMIA – a 2nd Multicenter Randomized Controlled Trial of the iFuse Implant System® vs Conservative Care

Aug 2, 2017

Results from Avedro's Corneal Collagen Cross-Linking Pivotal Phase 3 Corneal Ectasia Studies Published in Ophthalmology

Aug 2, 2017

CTI BioPharma Announces Completion of Enrollment in the Phase 3 PIX306 Trial of PIXUVRI® for Aggressive B-cell non-Hodgkin lymphoma

Aug 1, 2017

Affimed Reports Financial Results for Second Quarter 2017

Aug 1, 2017

Evaluations of the Analytical Performance of the Singulex Cardiac Troponin I Assay Used on its Single Molecule Counting Technology Platform Demonstrates Ability to Improve Cardio Vascular Disease Rule-Out

Aug 1, 2017

Keystone Heart Ltd to Accelerate Trials for Advanced Device to Protect Brain During Heart Procedures

Aug 1, 2017

Intellia Therapeutics Announces Second Quarter 2017 Financial Results

Aug 1, 2017

Rhythm Expands Executive Leadership Team

Aug 1, 2017

CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with Ruxolitinib

Aug 1, 2017

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2017 Financial Results

Jul 31, 2017

Invitae Acquiring Good Start Genetics and CombiMatrix, Adding Comprehensive Reproductive Health Capabilities to Serve Every Stage of Life

Jul 31, 2017

Intercept Announces Positive Results from the Phase 2 AESOP Trial Evaluating OCA for the Treatment of Patients with Primary Sclerosing Cholangitis

Jul 31, 2017

Loxo Oncology Announces Acquisition of Highly Selective, Reversible BTK Inhibitor Program

Jul 27, 2017

Cyrus Biotechnology Announces $8M Financing to Expand Computational Drug Discovery Software Platform

Jul 26, 2017

Sientra Completes Acquisition of Miramar Labs®

Jul 26, 2017

Verona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment

Jul 25, 2017

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing

Jul 25, 2017

Alpine Immune Sciences, Inc. Completes Merger with Nivalis Therapeutics, Inc.

Jul 25, 2017

Kala Pharmaceuticals Announces Close of Initial Public Offering and Exercise of Underwriters' Option

Jul 24, 2017

Dimension Therapeutics Announces Management Change

Jul 21, 2017

Leading Medical Physics Meeting to Feature First Presentations on Clinical Experience with ViewRay's MRIdian Linac

Jul 21, 2017

Pharming announces completion of its refinancing with a single US$100 million debt facility on improved commercial terms

Jul 20, 2017

First Patients Treated with ViewRay's MRIdian Linac System at Henry Ford Health System

Jul 20, 2017

Aeglea BioTherapeutics Announces Leadership Change

Jul 20, 2017

Kala Pharmaceuticals Announces Pricing of Initial Public Offering

Jul 18, 2017

Adimab Announces Platform Transfer with Lilly

Jul 18, 2017

Audentes Therapeutics Announces Appointment of Fulvio Mavilio, Ph.D. to Vice President Scientific Affairs, Europe

Jul 18, 2017

Otonomy Announces FDA Acceptance of OTIPRIO® Supplemental New Drug Application Filing for Acute Otitis Externa

Jul 18, 2017

Augmedix, powered by Glass, accelerates scaling efforts with the nation's leading healthcare systems

Jul 17, 2017

Symbiomix Therapeutics Announces Publication of Pivotal Data for Investigational Solosec™ for the Treatment of Bacterial Vaginosis

Jul 13, 2017

CTI BioPharma Announces European Medicines Agency Validation of Pacritinib Marketing Authorization Application for Patients with Myelofibrosis who have Thrombocytopenia

Jul 11, 2017

Roka Bioscience Announces AOAC Certification for 18-hour Sample Enrichment using ActeroTM ELITE Listeria Enrichment Media and the Atlas® Listeria Environmental Assay

Jul 11, 2017

Principia Biopharma Announces PRN1008 Receives Orphan Drug Designation From FDA For Treatment of Pemphigus Vulgaris

Jul 11, 2017

Nabriva Therapeutics Appoints Francesco Maria Lavino as Chief Commercial Officer

Jul 10, 2017

Roka Bioscience, Inc. Announces Co-Marketing and Supply Agreement with PURE Bioscience

Jul 10, 2017

Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer

Jul 6, 2017

Corvus Pharmaceuticals to Host R&D Day Highlighting Role of Adenosine Pathway in Immuno-Oncology

Jul 5, 2017

Pieris Pharmaceuticals Announces Results from 2017 Annual Meeting of Stockholders and Provides Update on Therapeutic Programs

Jul 5, 2017

SmartZyme Adds Two Drug Development Veterans to Broaden and Strengthen Leadership Team

Jun 30, 2017

SteadyMed submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead drug product candidate, Trevyent, for the treatment of Pulmonary Arterial Hypertension (PAH).

Jun 29, 2017

ARMO BioSciences Presents Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer at ESMO World Congress on Gastrointestinal Cancer 2017

Jun 29, 2017

Aerpio Announces Initiation of Patient Dosing in the TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic Retinopathy

Jun 29, 2017

ObsEva Announces Presentations Related to its Assisted Reproductive Technology (ART) and Pre-term labor (PTL) Development Programs at ESHRE 2017 Annual Meeting

Jun 29, 2017

FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder

Jun 28, 2017

Adicet Bio Appoints Jesse McGreivy, M.D., Chief Medical Officer

Jun 28, 2017

FutuRx portfolio cpmany, Mitoconix Bio gets $20M for mitochondrial dysfunction in neurodegeneration

Jun 27, 2017

Affimed Presents Preclinical Data on AFM24 and AFM26 at EACR-AACR-SIC 2017

Jun 27, 2017

Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across Europe

Jun 27, 2017

Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint

Jun 27, 2017

Rhythm and Camurus Announce Positive Initial Data for Extended-Release Delivery of Setmelanotide for the Treatment of Rare Genetic Disorders of Obesity

Jun 27, 2017

Dimension Therapeutics Completes Strategic Review And Updates Corporate Priorities

Jun 27, 2017

Marinus Pharmaceuticals Launches the Ganaxolone Clinical Program in Patients with Postpartum Depression

Jun 27, 2017

TP Therapeutics Announces FDA Orphan Drug Designation Granted to TPX-0005 for Treatment of Non-Small Cell Lung Adenocarcinomas Harboring ALK, ROS1, or NTRK Oncogenic Rearrangements

Jun 27, 2017

LogicBio Therapeutics Announces $50 Million in Financing to Develop Novel Gene Medicines for Pediatric Patients

Jun 26, 2017

Nabriva Therapeutics Appoints Carrie Bourdow and Colin Broom to the Board

Jun 26, 2017

Synlogic Receives Fast Track Designation in U.S. for Lead Candidate, SYNB1020

Jun 26, 2017

National Cancer Center Japan Treats First Patients Using ViewRay MRIdian System

Jun 22, 2017

Otonomy Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO® in Acute Otitis Media with Tympanostomy Tubes

Jun 21, 2017

Combining Implantation of Glaukos iStent inject® Trabecular Micro-Bypass with Topical Travoprost Provides Sustained IOP Reduction and Favorable Safety Profile, According to New Study

Jun 21, 2017

Avitide, Inc., Raises Series E Financing From Sands Capital Ventures With Broad Participation From Early Investors

Jun 21, 2017

Adimab Provides Mid-Year Update on 2017 Partnership Activity

Jun 20, 2017

Loxo Oncology Announces the Closing of its Follow-On Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Jun 20, 2017

Avedro Names Thomas E. Griffin Chief Financial Officer

Jun 19, 2017

Intellia Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China

Jun 19, 2017

Synlogic™ Doses First Subject in Phase 1 Trial of Novel Class of Synthetic Biotic™ Medicines

Jun 16, 2017

Tisbury Pharmaceuticals Raises $32M in Series A Financing

Jun 15, 2017

RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA�) for H. pylori Infection

Jun 14, 2017

RedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis

Jun 14, 2017

Alpine Immune Sciences Announces Presentation of Preclinical Data Showing Potency of Its First-Generation Dual ICOS and CD28 Antagonist vlgDs in an Animal Model

Jun 13, 2017

SI-BONE, Inc. Announces FDA Clearance and Full U.S. Commercial Launch of the iFuse-3DTM Implant, a Patented, 3D-Printed Next Generation Member of the iFuse Implant System

Jun 13, 2017

Abbvie And Principia Announce Collaboration On Oral Immunoproteasome Inhibitors

Jun 13, 2017

Audentes Therapeutics Appoints Jennifer Jarrett to Board of Directors

Jun 12, 2017

Sientra to Acquire Miramar Labs

Jun 12, 2017

Intercept Announces New Data Analysis From FLINT Trial of OCA in NASH Patients with Type 2 Diabetes

Jun 12, 2017

SI-BONE, Inc. Announces Blue Cross and Blue Shield of Vermont Establishes Positive Coverage Policy for MIS Sacroiliac Joint Fusion

Jun 12, 2017

Invitae Acquires CancerGene Connect, Award-Winning Risk Assessment and Family History Analysis Platform

Jun 9, 2017

MEDIGUS PRESENTS NEW DATA DEMONSTRATING THE MUSE™ SYSTEM IMPROVES GERD SYMPTOMS AND REDUCES PROTON PUMP INHIBITOR RELIANCE

Jun 8, 2017

Intellia’s Response to Nature Methods Article on CRISPR/Cas9

Jun 7, 2017

ObsEva SA Announces the Completion of a Phase 1 PK/PD Clinical Trial Evaluating Different Doses of OBE2109 and Add-Back Therapy

Jun 6, 2017

Synlogic Meets First Discovery Milestone in Partnership with AbbVie

Jun 6, 2017

Aeglea BioTherapeutics Prices Public Offering of Common Stock

Jun 6, 2017

Affimed Presents Data on First-in-Class BCMA-Targeting Immune Cell Engager AFM26 at ASCO Annual Meeting 2017

Jun 5, 2017

Sierra Oncology Reports Encouraging Initial Progress from Ongoing Phase 1 Clinical Trials of Chk1 Inhibitor SRA737

Jun 5, 2017

Adaptimmune Announces an Oral Presentation on Data from NY-ESO Study in Synovial Sarcoma and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 5, 2017

ASCO Data Shows Prostate Cancer Patients with Genetic Risk Factors Missed Under Current Testing Guidelines

Jun 5, 2017

Corvus Pharmaceuticals Announces Interim Results Demonstrating Anti-Tumor Activity of CPI-444 in Renal and Lung Cancer Patients Resistant or Refractory to Prior PD-(L)1 Treatment

Jun 5, 2017

Inspire Medical Systems Announces FDA Approval of Inspire 3028 Neurostimulator for the Treatment of Obstructive Sleep Apnea

Jun 5, 2017

TELA Bio to Present Surgeon Feedback from Initial Clinical Experience with OviTex™ Reinforced BioScaffolds and Product Permeability Data at Abdominal Wall Reconstruction Conference

Jun 5, 2017

Verona Pharma Initiates U.S. Clinical Pharmacokinetic Study for RPL554 Following Acceptance of IND Application by FDA

Jun 4, 2017

Pieris Pharmaceuticals Announces Presentation Of Clinical Data For Anemia Drug Candidate, PRS-080, At The 54Th ERA-EDTA Congress

Jun 3, 2017

ARMO BioSciences Announces Encouraging Survival Data Observed in Patients with Advanced Pancreatic Cancer in Phase 1/1b Trial of Immunotherapy AM0010

Jun 3, 2017

Loxo Oncology Announces Clinical Proof of Concept Publication for Next-Generation TRK Inhibitor LOXO-195

Jun 3, 2017

Loxo Oncology Breakthrough Therapy Larotrectinib Demonstrates 76 Percent Confirmed Objective Response Rate in TRK Fusion Adult and Pediatric Cancers as Presented at the American Society of Clinical Oncology

Jun 2, 2017

Nabriva Therapeutics to present data at ASM Microbe supporting ongoing Phase 3 clinical development program for lefamulin

Jun 1, 2017

Results from Avedro's Landmark Corneal Collagen Cross-Linking Pivotal Phase 3 Keratoconus Studies Published in Ophthalmology

Jun 1, 2017

BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination with Atezolizumab for Solid Tumors

May 30, 2017

Sierra Oncology Granted US and EU Patents for Chk1 inhibitor SRA737

May 26, 2017

STEADYMED RAISES ADDITIONAL CAPITAL FROM KEY INSTITUTIONAL SHAREHOLDER

May 23, 2017

Atox Bio’s Reltecimod Passes Futility Analysis in Phase 3 ACCUTE Study; Trial Continues as Planned

May 23, 2017

Bioverativ to Acquire Clinical-Stage Rare Disease Biotechnology Company, True North Therapeutics

May 23, 2017

Ascendis Pharma A/S Reports First Quarter 2017 Financial Results

May 23, 2017

Nabriva Commences Previously Announced Tender Offer Related to the Proposed Redomicile of its Holding Company from Austria to Ireland

May 22, 2017

Pieris Pharmaceuticals Appoints James Geraghty to its Board of Directors

May 22, 2017

Study Reveals Potential Cost Efficiency of Using Two Glaukos iStent® Trabecular Micro-Bypass Stents to Treat Elevated IOP in Glaucoma Patients

May 19, 2017

Intercept Receives Innovation Award from the National Organization for Rare Disorders for the Development of Ocaliva® (obeticholic acid)

May 18, 2017

Verona Pharma Announces Closing of Exercise of Underwriters’ Over-allotment Option

May 18, 2017

ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022

May 18, 2017

ObsEva Reports First Quarter 2017 Financial Results and Business Update

May 17, 2017

Affimed Reports Financial Results for First Quarter 2017

May 17, 2017

Loxo Oncology Announces Details of Two Larotrectinib Clinical Data Oral Presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

May 17, 2017

Rhythm Expands Phase 2 Clinical Trials of Setmelanotide to the Treatment of Bardet-Biedl Syndrome Obesity

May 17, 2017

Affimed to Present Immune Cell Engager Data at ASCO Annual Meeting and EACR-AACR-SIC Special Conference

May 16, 2017

Pharming announces refinancing of its existing debt by a single US$100 million debt facility on improved commercial terms

May 16, 2017

Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors

May 16, 2017

Practice Fusion to Present Real World Data on the Treatment of Diabetes and COPD at the ISPOR 22nd Annual International Meeting

May 16, 2017

Synlogic and Mirna Therapeutics Agree to Merger

May 16, 2017

5/16/17 - Aerpio Reports First Quarter 2017 Financial Results

May 15, 2017

Compelling Early Pancreatic Cancer Data with ViewRay’s MRIdian System Presented at ESTRO 36

May 15, 2017

ViewRay Reports First Quarter 2017 Financial Results

May 15, 2017

Corvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 in Renal and Lung Cancer at 2017 ASCO Annual Meeting

May 13, 2017

Intellia Therapeutics Announces Progress with CRISPR/Cas9 at the American Society of Gene & Cell Therapy Annual Meeting

May 12, 2017

Loxo Oncology Announces FDA Orphan Drug Designation Granted to Larotrectinib for the Treatment of Solid Tumors with NTRK-Fusion Proteins

May 12, 2017

Otonomy Announces OTIPRIO® Data Presentation and Symposium at the American Society of Pediatric Otolaryngology Annual Meeting

May 11, 2017

Rhythm Receives Expanded FDA Breakthrough Therapy Designation for Setmelanotide for Rare Genetic Disorders of Obesity

May 11, 2017

Good Start Genetics Deepens Relationship with Amazon offering a First of its Kind Online Ashkenazi Jewish Carrier Screening Test - See more at: https://www.goodstartgenetics.com/media-investors/genetic-screening-news/#sthash.D5vt0De1.dpuf

May 11, 2017

Roka Bioscience Reports First Quarter 2017 Financial Results

May 11, 2017

Guardant Health Partners with SoftBank to Accelerate Efforts in Early Cancer Detection

May 11, 2017

Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update

May 11, 2017

FutuRx portfolio cpmany,  BiomX Ltd. has secured $24 million in a Series A financing

May 10, 2017

Otic Pharma Completes Merger with Tokai Pharmaceuticals Company Renamed Novus Therapeutics, Inc; NASDAQ Ticker "NVUS"

May 10, 2017

Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting AFP in Liver Cancer

May 10, 2017

Dimension Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update

May 10, 2017

Loxo Oncology Announces Enrollment of First Patient in Phase 1 Clinical Trial for Highly Selective RET Inhibitor, LOXO-292

May 10, 2017

Pieris Pharmaceuticals Reports Financial Results for the First Quarter Ended March 31, 2017 and Provides Corporate Update

May 10, 2017

Adaptimmune Reports First Quarter 2017 Financial Results

May 10, 2017

Sierra Oncology Receives Clearance to Enhance Ongoing Clinical Trials for SRA737

May 9, 2017

Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update

May 9, 2017

Sierra Oncology Reports First Quarter 2017 Results

May 9, 2017

Loxo Oncology Announces First Quarter 2017 Financial Results

May 9, 2017

Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2017 Financial Results

May 9, 2017

Corvus Pharmaceuticals and Monash University Enter into Exclusive License Agreement for Novel Immuno-Oncology Program

May 8, 2017

Graybug Vision’s Potential Once-Per-Year AMD Treatment Data Presented at ARVO 2017

May 8, 2017

SI-BONE, Inc. Announces U.S. Military's TRICARE Now Covers MIS SI Joint Fusion

May 8, 2017

Roka Bioscience, Inc. Announces Distribution Partnership with FoodChek Systems Inc.

May 8, 2017

Audentes Therapeutics Announces Appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific Officer

May 8, 2017

Valerie Smith Joins Graybug Vision as VP, Global Clinical Development Operations

May 8, 2017

Invitae Exceeds 26,000 Samples Accessioned, Reports Revenue of $10.3 Million and Net Loss of $0.64 Per Share in First Quarter 2017

May 4, 2017

Intercept Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update

May 4, 2017

Otonomy Reports First Quarter 2017 Financial Results and Provides Corporate Update

May 4, 2017

Rhythm Starts Phase 3 Clinical Trial of Setmelanotide for Rare Genetic Disorder of Obesity

May 4, 2017

Avedro Launches Comprehensive Effort to Secure Coverage and Facilitate Reimbursement of FDA-Approved Corneal Cross-Linking Treatment

May 4, 2017

Corvus Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update

May 3, 2017

Pieris Pharmaceuticals and AstraZeneca Collaborate to Develop and Commercialize Anticalin-Based Inhaled Treatments for Respiratory Diseases

May 3, 2017

Glaukos Corporation Announces First Quarter 2017 Financial Results

May 3, 2017

Audentes Therapeutics Announces Presentation of Data at the American Society of Gene and Cell Therapy Annual Meeting

May 3, 2017

Glaukos Completes Patient Enrollment in Phase II Clinical Trial for iDose™ Travoprost Intraocular Implant in Glaucoma Patients

May 3, 2017

BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA

May 3, 2017

Acutus Medical® Receives FDA Clearance for AcQGuide™ Steerable Sheath

May 2, 2017

SteadyMed Receives USPTO Notice of Allowance for Patent Related to Key PatchPump® Technology

May 2, 2017

Intellia Therapeutics Announces First Quarter 2017 Financial Results

May 2, 2017

Corvus Pharmaceuticals Expands CPI-444 Clinical Collaboration with Genentech

May 2, 2017

ViewRay Showcases World’s First Commercially Available MRI-Guided Linac System at Leading European Radiation Oncology Meeting

May 2, 2017

Roka Bioscience to Present and Exhibit at the 2017 Food Safety Summit

May 2, 2017

Verona Pharma Announces Closing of Global Offering

May 1, 2017

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2017 Financial Results

May 1, 2017

Several Surgeon Presentations to Include Glaukos Technologies at 2017 American Society of Cataract and Refractive Surgery

May 1, 2017

SI-BONE, Inc. Announces SI Joint Fusion Study Showed Patients Were 11X Less Likely to be Taking Opioids at Last Follow-Up Using the iFuse Implant

May 1, 2017

Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract Surgery

Apr 28, 2017

New research suggests current genetic testing guidelines may miss breast cancer patients who could benefit from testing

Apr 28, 2017

Acutus Medical® Announces Completion of Enrollment for UNCOVER AF™ Study of AcQMap® in Persistent Atrial Fibrillation

Apr 27, 2017

Avedro Announces $42 Million in Funding to Support Commercial Expansion and Pipeline Development

Apr 26, 2017

Arsanis Completes $45.5 Million Series D Financing

Apr 26, 2017

Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy

Apr 26, 2017

Intellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein Complexes

Apr 26, 2017

John Tucker Appointed as Chief Executive Officer of scPharmaceuticals

Apr 25, 2017

ObsEva SA Initiates Phase 3 Clinical Program for OBE2109 in Uterine Fibroids

Apr 24, 2017

Allied Physicians Group and Tyto Care Sign Agreement to Bring Remote Telehealth Exams to Allied’s Vast Network of Patients

Apr 24, 2017

ReViral Announces Good Safety and Pharmacokinetics From Phase 1 Programme for RSV Antiviral RV521 in Healthy Volunteers

Apr 24, 2017

SI-BONE, Inc. Announces Publication of 6-year Clinical Results Demonstrating Long-Term Positive Outcomes of iFuse Implant System

Apr 24, 2017

Dimension Therapeutics Announces Presentations at the Upcoming American Society for Gene and Cell Therapy (ASGCT) Annual Meeting

Apr 24, 2017

Paratek Pharmaceuticals and Zai Lab Announce Collaboration, Development and License Agreement for Omadacycline in China

Apr 24, 2017

RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA Phase II Study for IBS-D

Apr 21, 2017

STEADYMED RAISES $30 MILLION IN PRIVATE PLACEMENT

Apr 20, 2017

ARMO BioSciences Announces Clinical Data Presentations for Immunotherapy AM0010 at ASCO 2017 Annual Meeting

Apr 20, 2017

Invitae announces expansion of its genetic test menu with addition of new tests and expanded panels for inherited metabolic and immune system disorders, including panels to confirm diagnoses suggested by newborn screening

Apr 20, 2017

Arsanis Announces Initial Clinical Data for ASN100 to be Presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases

Apr 19, 2017

Oxford Finance Provides $20 Million Senior Debt Facility to Cerapedics Inc

Apr 19, 2017

Verona Pharma Announces Launch of Global Offering and Application to List on the NASDAQ Global Market

Apr 19, 2017

Intercept Announces New Ocaliva® (obeticholic acid) and INT-767 Data to be Presented at EASL 2017

Apr 18, 2017

Carl Gordon named to 2017 Forbes Midas List

Apr 18, 2017

Jonathan Silverstein named to 2017 Forbes Midas List

Apr 18, 2017

Audentes Therapeutics Announces Pricing of Public Offering of Common Stock

Apr 18, 2017

Nivalis Therapeutics and Alpine Immune Sciences agree to combine

Apr 18, 2017

Verona Pharma Receives Authorization from the U.S. FDA to Proceed with Clinical Investigation of RPL554 with the Acceptance of Investigational New Drug Application

Apr 17, 2017

Singulex Announces $50 Million Senior Secured Debt Facility with Perceptive Advisors

Apr 17, 2017

Nabriva Announces the Proposed Redomicile of its Holding Company from Austria to Ireland, by means of an Exchange Offer

Apr 13, 2017

International Study Shows Two Glaukos iStent® Trabecular Micro-Bypass Stents and One Topical Medication Deliver Sustained IOP Reduction

Apr 13, 2017

ViewRay Announces $15.0 Million Capacity Expansion of its Term Loan Agreement

Apr 13, 2017

Miami Children’s Health System and Tyto Care to Expand Telehealth Services for Home Consumers

Apr 13, 2017

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board Decision

Apr 12, 2017

Glaukos Corporation Acquires IOP Sensor System from DOSE Medical

Apr 11, 2017

Dr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical Officer

Apr 11, 2017

Nabriva Therapeutics Announces Enrollment Completion for LEAP 1, a Phase 3 Clinical Trial Evaluating Lefamulin in Community-Acquired Bacterial Pneumonia

Apr 11, 2017

Intellia Therapeutics Announces European Patent Office’s Decision to Grant CRISPR/Cas9 Genome Editing Technology Patent

Apr 11, 2017

Tricida Announces Hiring of Geoffrey Parker as Chief Financial Officer and Senior Vice President

Apr 11, 2017

Rhythm Appoints Head of Sanofi Genzyme, Dr. David Meeker, as Chairman of Board of Directors

Apr 10, 2017

Adaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct Offering

Apr 10, 2017

Ganaxolone IV Clinical Data Presented at Leading International Status Epilepticus Medical Conference

Apr 9, 2017

CE MARK GRANTED TO NUCLEIX’S BLADDER EPICHECK – ANNOUNCING SUPERIOR RESULTS OVER ALL OTHER NON-INVASIVE TESTS IN A EUROPEAN MULTI-CENTER STUDY FOR BLADDER CANCER MONITORING

Apr 7, 2017

SI-BONE, Inc. Announces Published Guidance Recommendation for Minimally Invasive SI Joint Fusion from the National Institute for Health and Care Excellence (NICE)

Apr 6, 2017

Invitae expands its Genome Network with the launch of the Invitae Patient Insights Network (PIN), enabling participants to share health information and contribute to research

Apr 5, 2017

Practice Fusion Names Seasoned Health IT Executive Bevey Miner as New Chief Marketing Officer

Apr 5, 2017

RedHill Biopharma Announces Exclusive U.S. License from Entera Health for Commercial GI Product EnteraGam

Apr 5, 2017

True North Expands Leadership Team to Advance Pipeline of Novel Rare Disease Treatments Targeting the Complement System

Apr 5, 2017

Affimed Presents Data on Immune Cell Engager Pipeline at the AACR Annual Meeting 2017

Apr 4, 2017

Pieris Pharmaceuticals Presents IND-enabling Data for Bispecific Immuno-Oncology Drug Candidate, PRS-343, in Poster Session at the 2017 Meeting of the American Association for Cancer Research (AACR)

Apr 4, 2017

Corvus Pharmaceuticals Announces Interim Results from Ongoing Phase 1/1b Study Demonstrating Safety and Clinical Activity of Lead Checkpoint Inhibitor CPI-444 in Patients with Advanced Cancers

Apr 3, 2017

Singulex Announces CE Mark for Sgx Clarity® System

Apr 3, 2017

Sierra Oncology Collaborator ICR Reports Preclinical Synthetic Lethality Data for Chk1 Inhibitor SRA737 at AACR

Apr 3, 2017

SI-BONE, Inc. Announces 50th Peer-Reviewed Publication for the iFuse Implant System® and 25,000th iFuse Procedure Performed Worldwide

Apr 3, 2017

Ascendis Pharma A/S Showcases New Data on Rare Disease Product Pipeline at ENDO 2017

Apr 3, 2017

Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT132 to Treat X-Linked Myotubular Myopathy

Apr 3, 2017

Invitae announces new partnership with Alnylam Pharmaceuticals to provide TTR gene testing for patients suspected of having hereditary ATTR amyloidosis

Mar 31, 2017

Loxo Oncology Announces Proof of Concept Clinical Data for Larotrectinib in TRK Fusion Glioblastoma Presented at the AACR Annual Meeting 2017

Mar 30, 2017

GE Healthcare & Zai Lab Enter a Strategic Partnership to Co-Develop a World Class Biotherapeutics Clinical Production Center

Mar 30, 2017

Promentis Pharmaceuticals, Inc. Announces $26M Series C Financing and Elects Four New Board Members

Mar 29, 2017

Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting

Mar 29, 2017

ARMO BioSciences Announces First Patient Dosed in Pivotal Phase 3 Trial of Immunotherapy AM0010 for Advanced Pancreatic Cancer

Mar 28, 2017

Phase 2 Part A Open Label Extension Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva Continues Positive Trends

Mar 24, 2017

EU-funded consortium led by Immatics and BioNTech announces completion of regular study treatment in the GAPVAC-101 trial

Mar 23, 2017

Aeglea BioTherapeutics to Present Topline Data from Phase 1 Trial of AEB1102 for Treatment of Arginase I Deficiency at 2017 ACMG Annual Clinical Genetics Meeting

Mar 23, 2017

Singulex Expands Collaboration with European Clinical Laboratories to Demonstrate Applications and Opportunity of Sgx ClarityTM System

Mar 23, 2017

Symbiomix Therapeutics Announces FDA’s Acceptance of New Drug Application for Solosec™ with Priority Review Status

Mar 23, 2017

Affimed Announces Fourth Quarter and Year End 2016 Financial Results and Corporate Update Conference Call

Mar 23, 2017

Invitae Expands Test Menu for Proactive Genetic Testing in Healthy Adults

Mar 22, 2017

Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares

Mar 22, 2017

Pieris Pharmaceuticals Reports Full-Year 2016 Financial Results and Corporate Update

Mar 22, 2017

Ascendis Pharma A/S Reports Full Year 2016 Financial Results

Mar 22, 2017

Invitae announces expansion of its genetic testing offering to include unique test for Spinal Muscular Atrophy (SMA) during the 2017 ACMG Annual Clinical Genetics Meeting

Mar 22, 2017

Synlogic to Present at 2017 American College of Medical Genetics and Genomics Annual Meeting

Mar 22, 2017

Leading Family Genomics Company Good Start Genetics Expands Payor Relationships to More than 130 Million Covered Lives

Mar 21, 2017

argenx announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoimmune diseases

Mar 20, 2017

Loxo Oncology Announces Larotrectinib Pan-TRK IHC Companion Diagnostic Collaboration with Ventana Medical Systems, Inc., a member of the Roche Group

Mar 20, 2017

Corvus Pharmaceuticals to Present Data That Advances the Understanding of the Adenosine Pathway in Immuno-Oncology, including New Clinical Data on CPI-444 at AACR 2017

Mar 20, 2017

Audentes Therapeutics Announces Presentation Of Data From RECENSUS, A Medical Chart Review Of Patients With X-Linked Myotubular Myopathy (XLMTM)

Mar 17, 2017

ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor

Mar 16, 2017

ViewRay Reports Fourth Quarter and Full Year 2016 Financial Results

Mar 16, 2017

Glaukos Announces Five-Year Extensions for Three Category III CPT Codes Related to Micro-Invasive Glaucoma Surgery

Mar 16, 2017

Aerpio Pharmaceuticals Raises $40 Million

Mar 15, 2017

argenx reports fourth quarter business update and full year 2016 financial results

Mar 15, 2017

Adaptimmune Broadens Executive Team

Mar 14, 2017

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results

Mar 14, 2017

Invitae to present seventeen posters and presentations at the 2017 American College of Medical Genetics Annual Clinical Genetics Meeting

Mar 13, 2017

Adaptimmune Reports Fourth Quarter and Full Year 2016 Financial Results

Mar 13, 2017

NeRRe Therapeutics appoints Dr Steve Pawsey as Chief Medical Officer

Mar 13, 2017

Marinus Pharmaceuticals Provides Business Update and 2016 Financial Results

Mar 10, 2017

Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update

Mar 9, 2017

Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

Mar 9, 2017

Roka Bioscience Reports Fourth Quarter and Full Year 2016 Financial Results

Mar 9, 2017

Dimension Therapeutics Announces Full Year 2016 Financial Results and Recent Updates Across Rare and Metabolic Disease Portfolio and in HeLa Manufacturing

Mar 8, 2017

Intellia Therapeutics Demonstrates Pioneering CRISPR/Cas9 Genome Editing Efficiency Data Using Lipid Nanoparticle Delivery Technology

Mar 8, 2017

SI-BONE, Inc. Launches SI Joint Women's Health Initiative at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego, March 14 - 17

Mar 8, 2017

Xenon Pharmaceuticals Reports 2016 Financial Results and Provides Corporate Update

Mar 7, 2017

ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART

Mar 7, 2017

Loxo Oncology Reports Fourth Quarter and Year-End 2016 Financial Results

Mar 6, 2017

argenx announces that Staten Biotech exercised its option to develop therapeutic SIMPLE AntibodyTM for dyslipidemia

Mar 6, 2017

Keystone Heart Applauds FDA Advisory Panel

Mar 6, 2017

Keystone Heart and Venus MedTech Announce Partnership for Cerebral Embolic Protection with Transcatheter Heart Valve Systems (TAVR) in China and Key Asian Markets

Mar 6, 2017

Pieris Pharmaceuticals Announces Presentation of IND-enabling Data for Bispecific Immuno-Oncology Drug Candidate, PRS-343, at the 2017 Meeting of the American Association for Cancer Research (AACR)

Mar 2, 2017

NICE Recommends Ocaliva® (obeticholic acid) for the Treatment of Patients with Primary Biliary Cholangitis in England, Wales and Northern Ireland

Mar 2, 2017

Otonomy Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

Mar 2, 2017

Sierra Oncology Reports 2016 Year-End Results

Mar 1, 2017

argenx announces intention to conduct a registered public offering in the United States

Mar 1, 2017

Glaukos Corporation Announces Fourth Quarter & Full Year 2016 Financial Results

Mar 1, 2017

Adaptimmune Cuts Ribbon on U.S. Headquarters at the Navy Yard in Philadelphia

Mar 1, 2017

Audentes Therapeutics Announces Commencement of LUSTRO, a Clinical Assessment and Phase 1 / 2 Run-in Study of Patients with Crigler-Najjar Syndrome

Feb 28, 2017

OrbiMed Logs Two Decades of Novel Attacks on Cancer

Feb 28, 2017

Glaukos Technologies Featured in Eight Presentations at 2017 American Glaucoma Society Meeting

Feb 28, 2017

Ascendis Pharma A/S Announces Multiple Poster Presentations at ENDO 2017

Feb 27, 2017

ArGEN-x announces extension of therapeutic antibody alliance with Shire

Feb 27, 2017

ViewRay Receives FDA 510(k) Clearance for MRIdian Linac

Feb 27, 2017

Arsanis and Adimab Enter Into License Agreement to Target Respiratory Syncytial Virus (RSV) With Monoclonal Antibodies

Feb 27, 2017

Arsanis and Adimab Enter Into License Agreement to Target Respiratory Syncytial Virus (RSV) With Monoclonal Antibodies

Feb 27, 2017

PIERIS SIGNS 1ST PARTNERSHIP FOR ANEMIA DRUG PRS-080, GRANTING EXCLUSIVE OPTION IN JAPAN TO ASKA PHARMACEUTICAL

Feb 23, 2017

Intercept Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Business Update

Feb 22, 2017

Preeminent Ophthalmologist, L. Jay Katz Joins Glaukos Corporation as Chief Medical Officer

Feb 22, 2017

Symbiomix Therapeutics Appoints David L. Stern as Chief Executive Officer

Feb 22, 2017

PMV Pharma Secures $74 Million in Series B Financing for Cancer Drugs Targeting p53

Feb 21, 2017

Loxo Oncology Announces Completion of Clinical Trial Enrollment for Larotrectinib NDA Primary Efficacy Analysis

Feb 17, 2017

New research suggests broader genetic testing of prostate cancer patients may be warranted to identify risk of an inherited mutation that might inform treatment

Feb 17, 2017

Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC at ASCO 2017 Genitourinary Cancers Symposium

Feb 16, 2017

Rhythm Announces Completion of $41 Million Mezzanine Financing

Feb 16, 2017

TigerText Launches Role-based Scheduling Automation

Feb 16, 2017

Glaukos Completes Patient Enrollment in Pivotal Phase of U.S. IDE Clinical Trial for iStent SUPRA®

Feb 16, 2017

Ascendis Pharma A/S Announces Publication of Comprehensive Results from Randomized, Active-Controlled Phase 2 Trial of Once-Weekly TransCon Growth Hormone in Pediatric Patients

Feb 15, 2017

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K.

Feb 14, 2017

Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model

Feb 14, 2017

Practice Fusion Launches EHR-integrated Post-Marketing Active Safety Surveillance Program

Feb 13, 2017

Invitae reports revenue of $9.2 million in fourth quarter 2016 and projects strong volume and revenue growth in 2017

Feb 13, 2017

RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis

Feb 10, 2017

Intercept to Provide Update on Phase 3 REGENERATE Trial of Obeticholic Acid for the Treatment of NASH Patients with Liver Fibrosis

Feb 8, 2017

New Study at Leading Children’s Medical Center Finds TytoCare Telehealth Exams Equivalent to In-Clinic Exams

Feb 7, 2017

Pieris Announces Management Transition

Feb 6, 2017

Sonendo® Acquires PIPStek™ LLC

Feb 6, 2017

Joseph Gilliam to Join Glaukos Corporation as Chief Financial Officer and Senior Vice President of Corporate Development

Feb 2, 2017

OrbiMed Comments on Immunomedics Proxy Contest

Feb 2, 2017

Nabriva Therapeutics Confirms No Sample Size Adjustment Required for LEAP 1 Phase 3 Trial of Lefamulin in Community Acquired Bacterial Pneumonia

Feb 1, 2017

Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT342 to Treat Crigler-Najjar Syndrome

Feb 1, 2017

Glaukos Corporation Promotes Chris M. Calcaterra to Chief Operating Officer

Jan 31, 2017

DIMENSION ANNOUNCES INTERIM TOPLINE RESULTS FROM ONGOING PHASE 1/2 CLINICAL PROGRAM FOR DTX101, DIMENSION’S LEAD AAV PRODUCT CANDIDATE IN DEVELOPMENT FOR ADULT PATIENTS WITH MODERATE/SEVERE TO SEVERE HEMOPHILIA B

Jan 27, 2017

Private Japanese Hospital Purchases ViewRay MRIdian System

Jan 25, 2017

ObsEva SA Announces Pricing of Initial Public Offering

Jan 25, 2017

"Affimed Announces Closing of Public Offering of Common Stock"

Jan 25, 2017

Roka Bioscience To Exhibit And Present At IPPE 2017 Poultry Expo

Jan 24, 2017

scPharmaceuticals Announces Start of SUBQ-HF NHLBI Study with Its Subcutaneous Furosemide Product

Jan 24, 2017

Arsanis Announces First Patient Dosed in Global Phase 2 Study of ASN100 for Prevention of Staphylococcus aureus Pneumonia

Jan 23, 2017

FierceMedicalDevices names Acutus Medical® as one of its “Fierce 15” Medical Device Companies of 2016

Jan 23, 2017

Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder

Jan 23, 2017

SI-BONE's iFuse Implant System® Requires Revision Surgery 5 Times Less Compared to SI Joint Fixation with Screws According to New Peer-Reviewed Clinical Publication

Jan 20, 2017

ARMO BioSciences Presents New Phase 1b Clinical Data for AM0010 in Advanced Pancreatic Cancer Patients at 2017 Gastrointestinal Cancers Symposium

Jan 19, 2017

German Research Foundation (DFG) Purchases ViewRay MRIdian Linac for University Clinic Heidelberg

Jan 19, 2017

Symbiomix Therapeutics Submits New Drug Application to US FDA for Solosec™ for the Treatment of BV

Jan 19, 2017

Otonomy Initiates Patient Enrollment in Phase 2 Clinical Trial of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss

Jan 18, 2017

Shareholder Circular for proposed consolidation, authority to issue new shares, adoption of new Articles and Notice of Meeting on 8 February 2017

Jan 18, 2017

Proposed new Articles for adoption at Meeting on 8 February 2017

Jan 18, 2017

ViewRay Raises $26.1 Million in Private Placement

Jan 17, 2017

Aeglea BioTherapeutics to Present New Data at 2017 ACMG Annual Clinical Genetics Meeting

Jan 17, 2017

BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer

Jan 17, 2017

Adicet Bio Appoints Anne Altmeyer as Chief Business Officer

Jan 17, 2017

ObsEva Expands Leadership Team and Board of Directors with Industry Veterans

Jan 17, 2017

Roka Bioscience Announces Transition of CEO Role from Paul Thomas to Mary Duseau

Jan 13, 2017

ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor

Jan 11, 2017

Boehringer Ingelheim and AmoyDx Collaborate to Initiate Blood-based EGFR Mutation Testing in China

Jan 11, 2017

Intellia Therapeutics Joins Genomics England's Industry Consortum

Jan 11, 2017

RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections

Jan 11, 2017

First US Service Members Treated with the Only FDA-Approved Cross-Linking Procedure in the U.S.

Jan 11, 2017

Good Start Genetics and Genome Medical Announce Partnership to Provide Genetic Counseling to Couples Undergoing Carrier Testing

Jan 11, 2017

Affimed Provides Update on NK-Cell Immuno-Oncology Platform

Jan 10, 2017

Loxo Oncology Announces the Closing of its Follow-On Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Jan 10, 2017

Singulex Enters into Collaboration with QIAGEN to Develop Companion Diagnostics

Jan 10, 2017

Adimab Provides Annual Update on 2016 Partnerships and Milestones

Jan 10, 2017

Corvus Pharmaceuticals Announces Expansion of Renal Cell Carcinoma Cohort in Ongoing Phase 1/1b Clinical Study of Lead Checkpoint Inhibitor CPI-444

Jan 9, 2017

Tricida Announces Positive Topline Phase 1/2 Clinical Trial Results for TRC101 in 135 Subjects with Chronic Kidney Disease and Metabolic Acidosis

Jan 9, 2017

Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies

Jan 9, 2017

Otonomy Provides Corporate and Product Pipeline Update

Jan 9, 2017

Adaptimmune Announces New Senior Vice President of Global Bio-Process and Development

Jan 9, 2017

Adaptimmune confirms GSK Nomination of Second Adaptimmune Target under Strategic Multi-Target Collaboration

Jan 9, 2017

Invitae announces new leadership structure to drive global growth

Jan 9, 2017

Audentes Therapeutics Provides Full Year 2017 Strategic Outlook and Financial Guidance

Jan 9, 2017

Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors

Jan 9, 2017

SI-BONE, Inc. Announces iFuse Implant System® Warranty Program in Support of Patients, Providers and Payors

Jan 9, 2017

argenx launches Phase II proof-of-concept study of ARGX-113 for the treatment of myasthenia gravis

Jan 8, 2017

Xenon Pharmaceuticals Outlines Key Milestones for 2017

Jan 7, 2017

Alector Announces Closing of Series D Financing – Total Capital Raised in 2015 Exceeds $60M

Jan 6, 2017

Invitae meets annual volume guidance, projects doubling of volume in 2017, accelerates Genome Network by acquiring scalable patient-centered data company

Jan 6, 2017

Invitae acquires patient-centered data company AltaVoice, creating new offerings to advance research and access to care for patients with inherited and rare diseases

Jan 6, 2017

Cleave Biosciences Promotes Kanya Rajangam to Chief Medical Officer

Jan 5, 2017

10th January 2017: NeRRe Therapeutics CEO, Dr Mary Kerr, presents at the Biotech Showcase, 9-11 January 2017, San Francisco, CA, USA

Jan 5, 2017

Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance

Jan 5, 2017

Otonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO® in Patients with Acute Otitis Externa

Jan 5, 2017

Loxo Oncology Prices Follow-On Offering of Common Stock

Jan 5, 2017

Adicet Bio Appoints Anne Altmeyer as Chief Business Officer

Jan 5, 2017

Marinus Provides Business Outlook for 2017

Jan 5, 2017

NeRRe Therapeutics raises £23 million in oversubscribed Series B financing round

Jan 5, 2017

Arvinas Appoints Dr. John Houston as President of Research and Development and Chief Scientific Officer

Jan 4, 2017

scPharmaceuticals Announces Closing of $45.6 Million in Series B Financing

Jan 4, 2017

Loxo Oncology Announces Proposed Public Offering of Common Stock

Jan 4, 2017

Affimed and MD Anderson Announce Clinical Immuno-Oncology Development Collaboration

Jan 4, 2017

Pionyr Immunotherapeutics Closes Financing with Focus on Developing Antibody-based Immuno-oncology Therapeutics

Jan 3, 2017

Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome

Jan 3, 2017

Corvus Pharmaceuticals Names Ian T. Clark, Former Genentech Chief Executive Officer, to Board of Directors

Jan 3, 2017

Graybug Vision Appoints Thomas S. Templeman, PhD, as Chief Operating Officer

Dec 29, 2016

argenx announces publication of seminal data supporting the therapeutic potential of ARGX-110 for acute myeloid leukemia in the Journal of Experimental Medicine

Dec 22, 2016

ARMO BioSciences’ Immunotherapy AM0010 Receives Orphan Designation in Europe for the Treatment of Pancreatic Cancer

Dec 22, 2016

Tokai Pharmaceuticals and Otic Pharma Enter into Share Purchase Agreement

Dec 21, 2016

Invitae announces major expansion of its pediatric, neurological, and rare disease genetic test offerings

Dec 20, 2016

Nabriva Achieves 60% Randomization Target in LEAP 1 Phase 3 Trial in Community Acquired Bacterial Pneumonia

Dec 20, 2016

Singulex Opens European Office and Advances IVD System Evaluation

Dec 19, 2016

Adaptimmune and Bellicum Pharmaceuticals Enter a Strategic Collaboration to Evaluate Next-Generation T-Cell Therapies

Dec 19, 2016

Nabriva Announces Closing of Rights Offering and Underwritten Offering

Dec 19, 2016

Loxo Oncology Outlines Plans for Accelerated Path to U.S. FDA Approval for Larotrectinib (LOXO-101) and Provides Comprehensive Pipeline Update

Dec 18, 2016

Loxo Oncology TRK Inhibitor Larotrectinib (LOXO-101) Shows Durable Anti-Tumor Activity Across TRK Fusion Cancers in ESMO Asia Phase 1 Update

Dec 16, 2016

Recro Pharma Announces Closing of $40 Million Public Offering of Common Stock

Dec 16, 2016

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global Agreement on the Foundational Intellectual Property for CRISPR/Cas9 Gene Editing Technology

Dec 15, 2016

Health Care Service Corporation (HCSC), the Fourth Largest Health Insurer in the United States, Establishes Exclusive Positive Coverage Policy for SI-BONE’s iFuse Implant System® for Minimally Invasive Sacroiliac Joint Fusion

Dec 15, 2016

argenx launches Phase I/II study of ARGX-110 in combination with azacitidine in newly diagnosed AML patients

Dec 15, 2016

SYNLOGIC APPOINTS COO and Head of Corporate Development

Dec 14, 2016

Nabriva Announces Results of Rights Offering and Pricing of Underwritten Offering

Dec 14, 2016

European Commission Grants Intercept's Ocaliva® (obeticholic acid) Marketing Authorization for the Treatment of Primary Biliary Cholangitis

Dec 14, 2016

Invitae sees increase in utilization of its inherited prostate cancer genetic tests

Dec 14, 2016

European Commission Grants Intercept's Ocaliva® (obeticholic acid) Marketing Authorization for the Treatment of Primary Biliary Cholangitis

Dec 13, 2016

Intellia Therapeutics Names Graeme Bell Chief Financial Officer

Dec 13, 2016

Audentes Therapeutics Appoints Julie Anne Smith to Board of Directors

Dec 13, 2016

Clinical Communications Platform Leader TigerText Announces Year of Record Growth with Over 300 New Healthcare Partnerships

Dec 13, 2016

DIMENSION THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR DTX301 TO TREAT OTC DEFICIENCY

Dec 12, 2016

SONENDO® CLOSES $35 MILLION EQUITY FINANCING ROUND

Dec 12, 2016

STUDY PUBLISHED IN JOURNAL OF GLAUCOMA EVALUATES A SINGLE GLAUKOS ISTENT® TRABECULAR MICRO-BYPASS STENT AS A STANDALONE PROCEDURE

Dec 12, 2016

Loxo Oncology to Present Updated LOXO-101 Adult Phase 1 Data at the European Society for Medical Oncology (ESMO) Asia Congress

Dec 9, 2016

Arvinas Presents Data on Oral Estrogen Receptor PROTAC Degrader at 2016 San Antonio Breast Cancer Symposium

Dec 9, 2016

Adimab Scientists Report the Isolation of Highly Potent anti-RSV Antibodies

Dec 8, 2016

Singulex and Thermo Fisher Scientific Enter into License and Supply Agreement to bring Next Generation Immunodiagnostics to Sepsis and SIRS Diagnostics

Dec 7, 2016

Invitae adds two genes, offers faster turnaround time for its Breast Cancer STAT Panel

Dec 6, 2016

Affimed Presents New Preclinical Data on Bi- and Trispecific Immune Cell Engagers at ASH

Dec 6, 2016

Arvinas Collaborators Present Data on BET PROTAC Degraders at 2016 ASH Annual Meeting

Dec 5, 2016

Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study

Dec 5, 2016

BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016

Dec 5, 2016

Dimension Therapeutics Announces Presentation at the 58th American Society of Hematology (ASH) Annual Meeting

Dec 3, 2016

True North Presents Additional Data from an Ongoing Clinical Study Showing Normalization of Hemoglobin Levels with TNT009 in Severely Anemic Cold Agglutinin Disease (CAD) Patients

Dec 3, 2016

Nutrinia Announces First Patient Enrolled in Phase III Trial

Dec 2, 2016

argenx to provide updates on ARGX-113 and ARGX-110 during American Society of Hematology Annual Meeting

Dec 1, 2016

Pieris Pharmaceuticals Appoints Claude Knopf as Chief Business Officer

Dec 1, 2016

Arsanis Receives FDA Fast Track Designation for ASN100 for the Prevention of Staphylococcus aureus Pneumonia

Dec 1, 2016

Intellia Therapeutics Opens New Headquarters as Company Continues to Advance CRISPR/Cas9 Platform and Pipeline

Nov 30, 2016

Cerapedics Announces Breakthrough Technology Agreement with Premier Inc.

Nov 30, 2016

Otonomy Appoints Kathie M. Bishop, Ph.D., as Chief Scientific Officer

Nov 30, 2016

Published Study Highlights MRIdian System’s Value in Sparing Healthy Tissue from Radiation

Nov 30, 2016

Ascendis Pharma A/S Reports Third Quarter 2016 Financial Results

Nov 29, 2016

Arvinas Presents Data on its BET PROTAC Degraders at 2016 EORTC-NCI-AACR Symposium

Nov 29, 2016

Dimension Therapeutics Receives Positive Opinion for European Orphan Drug Designation of DTX401 for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Nov 29, 2016

Nabriva Announces Terms of Rights Offering

Nov 29, 2016

Audentes Therapeutics Announces Initiation of Large-scale cGMP Production at its Gene Therapy Manufacturing Facility

Nov 28, 2016

Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam

Nov 23, 2016

Verona Pharma plans to conduct initial public offering in the US

Nov 22, 2016

Nabriva Announces Change in Record Date for Planned Rights Offering

Nov 21, 2016

BioLineRx In-licenses Novel Anti-Inflammatory Treatment for Dry Eye Syndrome Under Strategic Collaboration with Major Global Pharmaceutical Company

Nov 21, 2016

Aeglea BioTherapeutics Announces Publication in Nature Medicine Demonstrating that Targeting Tumor Oxidative Stress with AEB3103 Suppresses Cancer Growth in Preclinical Models

Nov 18, 2016

Cerapedics Receives Best New Technology Award for Spine Care at NASS Annual Meeting

Nov 18, 2016

Clementia Clinical Program: Necker Begins Enrolling Patients in Palovarotene 2B Extension Study

Nov 18, 2016

Clementia Announces Top-line Results from Phase 2 Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva

Nov 17, 2016

Invitae Announces Pricing of Public Offering of Common Stock

Nov 17, 2016

Xtant Medical Announces Expiration of Rights Offering and Estimated Gross Proceeds of $3.8 Million

Nov 16, 2016

Inspire Medical Systems Completes 1000th Implant, Names Marilyn Carlson Nelson to the Board, and Completes Series F Financing

Nov 16, 2016

Nabriva Reports Third Quarter 2016 Financial Results

Nov 15, 2016

GENEWIZ CHOSEN FOR THE INC. 5000 LIST OF FASTEST-GROWING PRIVATE COMPANIES FOR THIRD YEAR IN A ROW

Nov 15, 2016

Loxo Oncology to Present Preclinical Data for LOXO-292 and LOXO-195 at the 28th EORTC-NCI-AACR Symposium

Nov 15, 2016

Ganaxolone and Diazepam Administered Intravenously Synergistically Block Seizures in Animal Model of Status Epilepticus

Nov 15, 2016

Invitae Announces Proposed Public Offering of Common Stock

Nov 14, 2016

ViewRay Reports Third Quarter 2016 Financial Results

Nov 14, 2016

Clementia Clinical Program: Clinical Trial Site for Palovarotene Study Opened in Argentina

Nov 14, 2016

Clementia Clinical Program: Mayo Clinic Opens a Trial Site for Palovarotene Study

Nov 14, 2016

ARMO BioSciences’ Immunotherapy AM0010 Receives Orphan Drug and Fast Track Designations from the U.S. FDA for the Treatment of Pancreatic Cancer

Nov 11, 2016

Intercept Presents New Data at AASLD Examining the Effects of Ocaliva® (Obeticholic Acid) on Non-Invasive Assessments of Liver Fibrosis in Patients with PBC

Nov 11, 2016

Adaptimmune Announces Update on Clinical Data from NY-ESO SPEAR™ T-cell Synovial Sarcoma Study at the 2016 Annual Meeting of the Connective Tissue Oncology Society (CTOS)

Nov 11, 2016

Corvus Pharmaceuticals Announces Preliminary Phase 1/1b Clinical Data with Lead Checkpoint Inhibitor CPI-444 Demonstrating Safety and Evidence of Anti-Tumor Activity as a Single Agent in Patients with Advanced Refractory Cancers

Nov 11, 2016

Nabriva Announces Planned Rights Offering and Sets Record Date

Nov 11, 2016

Adaptimmune Presents Preclinical Data from a New, Wholly-owned SPEAR™ T-cell and a Second Generation SPEAR T-cell at the 31st Annual Meeting of the Society for Immunotherapy for Cancer (SITC)

Nov 10, 2016

Adaptimmune Reports Third Quarter 2016 Financial Results

Nov 10, 2016

Audentes Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update

Nov 10, 2016

Glaukos Completes Patient Enrollment In Initial Phase Of U.S. IDE Clinical Trial For Standalone Version Of iStent Inject®

Nov 10, 2016

Recro Pharma Reports Third Quarter 2016 Financial Results

Nov 10, 2016

Glaukos Corporation Announces Third Quarter 2016 Financial Results

Nov 10, 2016

Dimension Therapeutics Reports Recent Corporate Progress and Third Quarter 2016 Financial Results

Nov 10, 2016

OmniGuide Holdings, Inc. Hires John Markovich as CFO, Ajay Bhave as VP Operations and John Barnhill as VP Marketing & Business Development

Nov 10, 2016

Synlogic Secures Patent on Proprietary Synthetic Probiotic Bacteria for the Treatment of Hyperammonemia

Nov 9, 2016

Adaptimmune Announces Removal of Partial Clinical Hold in Myxoid/Round Cell Liposarcoma (MRCLS)

Nov 9, 2016

Loxo Oncology Appoints Steve D. Harr, M.D., CFO of Juno Therapeutics, to Board of Directors

Nov 9, 2016

Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2016 Financial Results

Nov 9, 2016

Pieris Pharmaceuticals Reports Financial Results and Provides Corporate Update for the Third Quarter Ended September 30, 2016

Nov 9, 2016

Natera Reports Third Quarter 2016 Financial Results

Nov 8, 2016

Adaptimmune Announces Appointment of Tal Zaks to Board of Directors

Nov 8, 2016

" Affimed to Present Preclinical Data on Bi- and Trispecific Immune Cell Engagers at ASH "

Nov 8, 2016

Aeglea BioTherapeutics to Present a Poster at the Society for Immunotherapy of Cancer 2016 Annual Meeting Suggesting Potential for AEB1102 Combination Therapy with Immuno-Oncology Checkpoint Inhibitors

Nov 8, 2016

New International Study Highlights Iop-Lowering Performance Of Glaukos iStent Inject® Trabecular Micro-Bypass In Standalone Procedure

Nov 8, 2016

Adaptimmune to Present Three Posters at the 31st Annual Meeting of the Society for Immunotherapy for Cancer (SITC)

Nov 7, 2016

Xtant™ Medical Holdings Reports Record Third Quarter 2016 Results

Nov 7, 2016

Invitae Announces Third Quarter 2016 Financial Results, Secures Contracts with Top Five Largest Payers, and Grows Volume More Than 200% Year-Over-Year

Nov 7, 2016

Roka Bioscience Reports Third Quarter 2016 Financial Results

Nov 4, 2016

Rhythm Presents Positive Initial Data for Setmelanotide in LepR Deficiency Obesity

Nov 3, 2016

Otonomy Reports Third Quarter 2016 Financial Results and Provides Corporate Update

Nov 3, 2016

Aeglea BioTherapeutics to Present New Data on AEB3103 at American Society of Hematology (ASH) 58th Annual Meeting

Nov 3, 2016

Atox Bio Announces Independent Safety Monitoring Committee Recommendation To Continue Phase 3 Study Of AB103 In Necrotizing Soft Tissue Infections

Nov 3, 2016

Corvus Pharmaceuticals Announces Third Quarter Financial Results and Provides Business Update

Nov 3, 2016

Intercept Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update

Nov 3, 2016

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2016 Financial Results

Nov 3, 2016

Xenon Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update

Nov 2, 2016

Corvus Pharmaceuticals to Present at SITC’s 31st Annual Meeting

Nov 2, 2016

CMS Publishes 2017 Final Hospital Outpatient and Ambulatory Surgical Center Payment Rule Increasing Outpatient Facility Reimbursement for MIS SI Joint Fusion Using SI-BONE's iFuse Implant System®

Nov 2, 2016

Affimed Reports Financial Results for Third Quarter 2016

Nov 2, 2016

Good Start Genetics Brings First Next-Generation Sequencing (NGS) Test to Amazon Enabling Broad Access to Carrier Screening for Couples Starting a Family

Nov 2, 2016

Delirium Significantly Associated with Brain Lesions in Patients Post-TAVR According to New Data Released at TCT 2016

Nov 2, 2016

Otonomy Announces Assignment of J Code for OTIPRIO®

Nov 2, 2016

Loxo Oncology Announces Third Quarter 2016 Financial Results

Nov 1, 2016

Intellia Therapeutics Reports Financial Results for Third Quarter 2016

Nov 1, 2016

Intercept Announces Ocaliva® (Obeticholic Acid) Data in PBC to be Presented at the 2016 AASLD Annual Meeting

Oct 31, 2016

iStent® Trabecular Micro-Bypass Stent Reduced Iop And Medication Use In Predominately Hispanic Glaucoma Patient Population, According To Published Study

Oct 31, 2016

ReViral initiates Phase 1 clinical trial of potent oral inhibitor against Respiratory Syncytial Virus

Oct 31, 2016

Nabriva Presents Research on Lefamulin at IDWeek 2016™

Oct 27, 2016

SI-BONE, Inc. Announces SelectHealth of Utah to Cover Minimally Invasive Sacroiliac Joint Fusion Exclusively Using the iFuse Implant System® as the Only Proven Technology

Oct 27, 2016

Adaptimmune Announces Board Changes

Oct 27, 2016

Adaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDA® (pembrolizumab) in Combination with NY-ESO SPEAR® T-Cell Therapy in Multiple Myeloma

Oct 27, 2016

Arsanis to Present Data at IDWeek 2016 Demonstrating Lack of Effectiveness of Standard Antibiotics on Progression to Staphylococcus aureus Pneumonia in Hospitalized, High-Risk Patients

Oct 27, 2016

argenx Reports Third Quarter 2016 Financial Results and Provides Business Update

Oct 26, 2016

Pieris Pharmaceuticals to Receive GLP Tox Milestone Payment in Daiichi Sankyo Collaboration

Oct 26, 2016

Verona Pharma receives second Award from Cystic Fibrosis Trust

Oct 26, 2016

Acutus Medical® Announces First Patient Procedure in Pivotal Atrial Fibrillation Trial (UNCOVER-AF) and Introduction of the World’s First ElectroFunctional™ Procedure

Oct 25, 2016

Symbiomix Therapeutics Data Presented on Clinician/Patient Perspectives of Bacterial Vaginosis at International Society for Quality of Life Research 23rd Annual Conference

Oct 24, 2016

ObsEva Announces Results Of The Implant Phase 2 Trial Of OBE001 (Nolasiban) For The Improvement Of Pregnancy And Live Birth Rates Following IVF/ICSI

Oct 24, 2016

Frost & Sullivan Applauds GENEWIZ's Commitment to Providing Cutting-edge Services in the Life Science Research Services Market

Oct 24, 2016

Unilife Announces Filing of 2016 10-K

Oct 20, 2016

TigerText Introduces TigerFlow, The Next Evolution In Clinical Communications

Oct 19, 2016

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

Oct 19, 2016

Ganaxolone Phase 1 Data Supports Progressing to Phase 2 in Patients with Status Epilepticus

Oct 19, 2016

Invitae announces multiple scientific presentations and posters to be presented at the American Society of Human Genetics 2016 Annual Meeting

Oct 18, 2016

Dimension Therapeutics Announces Presentations Highlighting Advances in AAV Manufacturing at the European Society of Gene and Cell Therapy (ESGCT) Congress

Oct 18, 2016

Practice Fusion Presents Results of Real World Evidence (RWE) Study on Treatments of Type 2 Diabetes at EASD Annual Meeting

Oct 18, 2016

Invitae announces collaboration with Helix to build applications for health and wellness

Oct 18, 2016

Adaptimmune Announces Initiation of Triple Tumor Study to Evaluate its SPEAR® T-Cell Therapy Targeting MAGE-A10

Oct 18, 2016

Good Start Genetics to Present New Scientific Findings at The American Society of Human Genetics Conference

Oct 18, 2016

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

Oct 18, 2016

True North Therapeutics Announces $45 Million Series D Financing

Oct 17, 2016

ObsEva Announces Plans to Conduct Initial Public Offering in the United States

Oct 17, 2016

Good Start Genetics Introduces Most Affordable Preimplantation Genetic Screening (PGS) Test on the Market, Broadening Access for More Couples Planning a Family

Oct 14, 2016

Intellia Therapeutics to Present Data at the European Society of Gene & Cell Therapy Congress

Oct 14, 2016

Clementia Announces Top-line Results from Phase 2 Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva

Oct 14, 2016

" Intercept Pharmaceuticals Receives Positive CHMP Opinion for Ocaliva® (Obeticholic Acid) for the Treatment of Primary Biliary Cholangitis in the European Union"

Oct 13, 2016

Cynapsus Therapeutics Securityholders Approve the Plan of Arrangement with Sunovion Pharmaceuticals

Oct 13, 2016

MRIdian Clinical Outcomes Data and Adaptive Capabilities: Highlights from ASTRO 2016

Oct 13, 2016

True North Therapeutics Receives FDA Orphan Drug Designation for TNT009 for the Treatment of Autoimmune Hemolytic Anemia, Including Cold Agglutinin Disease (CAD)

Oct 12, 2016

Adaptimmune Provides Update on Clinical Study Evaluating its SPEAR® T-Cell Therapy Targeting NY-ESO-1 in Ovarian Cancer

Oct 11, 2016

Dimension Therapeutics Announces Presentations at the Upcoming European Society of Gene and Cell Therapy (ESGCT) Congress

Oct 11, 2016

Roka Bioscience, Inc. Announces One-For-Ten Reverse Stock Split

Oct 10, 2016

Corvus Pharmaceuticals Announces Biomarker Findings from Phase 1/1b Study of Lead Oral Checkpoint Inhibitor CPI-444 Presented at ESMO 2016 Congress

Oct 6, 2016

Glaukos Technologies Featured In Various Presentations At 2016 American Academy Of Ophthalmology Conference

Oct 5, 2016

Frost & Sullivan Applauds argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPLE Antibody™

Oct 5, 2016

SI-BONE, Inc. Continues Leadership in Clinical Evidence Transparency Initiative Adding INSITE 2-Year RCT Results to Yale University Open Data Access Program

Oct 5, 2016

RedHill Announces Initiation of Phase II Study with YELIVA™ in Hepatocellular Carcinoma at the Medical University of South Carolina

Oct 4, 2016

DIMENSION THERAPEUTICS ANNOUNCES ORPHAN DRUG DESIGNATION OF DTX401 FOR THE TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE IA (GSDIA)

Oct 4, 2016

Otonomy Successfully Completes Phase 2 Clinical Trial of OTIPRIO® in Pediatric Patients with Acute Otitis Media with Tympanostomy Tubes

Oct 4, 2016

Affimed Presents Preclinical Data on Lead Candidate AFM13 at the Annual Meeting of the Society for Natural Immunity

Oct 3, 2016

Invitae announces final Medicare pricing set at $925 for hereditary breast cancer-related disorders under new billing process

Oct 3, 2016

ReViral Announces Appointment of New Chief Executive Officer

Sep 30, 2016

American Journal of Cardiology Reports Data Showing New Brain Lesions in 94% of Patients Following TAVR

Sep 29, 2016

Cerapedics Announces Closing of Series D Financing

Sep 29, 2016

Ganaxolone Reduces Seizures in Females with PCDH19 Pediatric Epilepsy

Sep 28, 2016

Blue Cross Blue Shield of Nebraska Adopts Positive Coverage for Minimally Invasive Sacroiliac Joint Fusion

Sep 27, 2016

NEW STUDY UNDERSCORES ABILITY OF ISTENT® TRABECULAR MICRO-BYPASS STENT TO ACHIEVE SUSTAINED REDUCTIONS IN IOP AND MEDICATION USE IN GLAUCOMA PATIENTS UNDERGOING CATARACT SURGERY

Sep 27, 2016

Xenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Directors

Sep 26, 2016

Pieris Pharmaceuticals Presents Positive Data for Its Lead Bispecific Drug Candidate, PRS-343, at the 2016 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

Sep 26, 2016

MD Anderson Cancer Center and Adaptimmune Form Strategic Alliance to Advance Development of Immunotherapies Targeting Multiple Cancers

Sep 26, 2016

Sonendo® Appoints John "Jack" Glenn As Chief Financial Officer

Sep 22, 2016

Roka Bioscience, Inc. Completes Private Placement of Preferred Stock and Warrants

Sep 22, 2016

argenx provides update on lead programs in auto-immune disease and oncology at R&D day in New York

Sep 22, 2016

ViewRay MRIdian Clinical Experience to be highlighted by Five Leading Centers at Largest Radiation Oncology Meeting

Sep 21, 2016

National Cancer Center Japan Purchases ViewRay MRIdian System

Sep 19, 2016

OrbiMed Portfolio Companies Adicet Bio and Rhythm Pharma Ranked In Fierce 15

Sep 19, 2016

Adicet Bio Named as One of FierceBiotech’s “Fierce 15” Biotech Companies of 2016 

Sep 19, 2016

FierceBiotech Names Rhythm as a “Fierce 15” Biotechnology Company of 2016

Sep 19, 2016

TriGuard Cerebral Protection Device Demonstrates Safety and Significant Improvements in Brain Protection in Patients Undergoing TAVR Procedures

Sep 19, 2016

ViewRay Receives CE Mark Approval for its MRIdian Linac System

Sep 19, 2016

Adaptimmune Announces Strategic Manufacturing Agreement with PCT to Support Development of SPEAR® T-cell Therapies Towards Commercialization

Sep 19, 2016

Adicet Bio Named as One of FierceBiotech’s “Fierce 15” Biotech Companies of 2016

Sep 19, 2016

Intercept Pharmaceuticals Files New Drug Submission to Health Canada for Marketing Approval of Obeticholic Acid for the Treatment of Patients with Primary Biliary Cholangitis

Sep 19, 2016

Corvus Pharmaceuticals to Present Data on Lead Oral Checkpoint Inhibitor CPI-444 at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

Sep 15, 2016

Otonomy Successfully Completes Open-Label Clinical Trial for OTIPRIO® in Patients with History of Otitis Media Requiring Tympanostomy Tubes

Sep 15, 2016

Aeglea BioTherapeutics Doses First Patients in Phase 1 Trial of AEB1102 for the Treatment of Arginase I Deficiency

Sep 14, 2016

CUSTOMISABLE CHROMATOGRAPHY RESIN MAKER AVITIDE BOOSTED BY SERIES D FUNDING

Sep 13, 2016

Xenon Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Closing of $34.5 Million Public Offering

Sep 12, 2016

Synlogic Expands Leadership Team to Support Rapid Advancement of the First Synthetic Biotic Towards the Clinic

Sep 12, 2016

Two Studies Demonstrate Promising Results of PiXL™ Procedure (Photorefractive Intrastromal Corneal Collagen Cross-Linking) for Non-Invasive Treatment of Low Myopia

Sep 10, 2016

Two Studies Demonstrate Promising Results of PiXL™ Procedure (Photorefractive Intrastromal Corneal Collagen Cross-Linking) for Non-Invasive Treatment of Low Myopia

Sep 9, 2016

Ascendis Pharma A/S Announces Multiple TransCon Growth Hormone Presentations at the European Society of Paediatric Endocrinology Annual Meeting

Sep 8, 2016

Xenon Pharmaceuticals Announces Pricing of $30 Million Public Offering of Common Shares

Sep 8, 2016

Avedro Appoints Dr. Reza Zadno As Chief Executive Officer

Sep 7, 2016

Pieris Pharmaceuticals Announces Presentation of Data for Its Lead IO Bispecific Program, PRS-343, at the 2016 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

Sep 6, 2016

MULTIPLE SURGEONS TO PRESENT CLINICAL DATA REGARDING GLAUKOS GLAUCOMA DEVICES AT 2016 EUROPEAN SOCIETY OF CATARACT AND REFRACTIVE SURGEONS CONGRESS

Sep 6, 2016

Arsanis Announces Two Key Publications Supporting Its Lead Program ASN100

Sep 1, 2016

Together into the Future: Hocoma Merges with DIH International to Provide Total Solution for Modern Rehabilitation.

Aug 31, 2016

Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics

Aug 29, 2016

Cancer Upstart CBT closed $9.7M Series A; OrbiMed Lead Investor

Aug 29, 2016

Synlogic Proprietary Synthetic Biotic Receives FDA Orphan Drug Designation

Aug 29, 2016

Aeglea BioTherapeutics Doses First Patient in Phase 1 Trial of AEB1102 for the Treatment of Hematological Malignancies

Aug 29, 2016

Intellia Therapeutics’ Preclinical Data Show Continued Progress in In Vivo Gene Editing With Systemic Lipid Nanoparticle Delivery of CRISPR/Cas9 components

Aug 29, 2016

Cynapsus Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson’s Disease

Aug 24, 2016

Singulex Granted ISO 13485:2012 Certification

Aug 24, 2016

SI-BONE, Inc. Announces Two-Year Results from a Randomized Controlled Trial of the iFuse Implant System® vs. Non-Surgical Management for Some Causes of Sacroiliac Joint Dysfunction

Aug 22, 2016

Inspire Medical Systems Reaches Over 1,000 Implants for the Treatment of Obstructive Sleep Apnea

Aug 19, 2016

ViewRay Announces $13.75 Million Private Placement

Aug 17, 2016

New England Journal of Medicine Publishes Results of Phase 3 POISE Trial of Ocaliva® (Obeticholic Acid) for the Treatment of PBC

Aug 15, 2016

Cynapsus Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson’s Disease Clinical Study Allowing for At-Home Titration

Aug 15, 2016

ARMO BioSciences Announces Publication of AM0010 Clinical Data in Advanced Solid Tumor Patients in Journal of Clinical Oncology (JCO)

Aug 15, 2016

Invitae announces major expansion of its neurology and cardiology test offerings

Aug 12, 2016

Cynapsus Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease

Aug 11, 2016

Ascendis Pharma A/S Initiates Phase 3 Registration Trial for TransCon Growth Hormone in Children with Growth Hormone Deficiency

Aug 10, 2016

OmniGuide Holdings Completes Merger of OmniGuide & Domain Surgical

Aug 10, 2016

ORIC Pharmaceuticals Appoints Ashraf Hanna, PhD, MD, as Chief Executive Officer, and Darcy Mootz, PhD, as Chief Business Officer

Aug 9, 2016

Sientra® Provides Update on Manufacturing Solution

Aug 9, 2016

Nabriva Reports Second Quarter 2016 Financial Results

Aug 8, 2016

Clementia Clinical Program: Opportunity for New Adult and Older Adolescent Subjects to Enroll in Palovarotene Study

Aug 8, 2016

Cleave Biosciences Raises $37 Million Series B Financing

Aug 8, 2016

First Scientific Presentations on ViewRay’s MRIdian Linac Technology

Aug 3, 2016

Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR® T-cell Therapy in Myxoid Round Cell Liposarcoma

Aug 3, 2016

Loxo Oncology Announces Second Quarter 2016 Financial Results

Aug 3, 2016

"With Pediatric Scientific Advisory Board, Good Start Genetics Plots a Course to Expanded Markets in Family Care"

Aug 1, 2016

Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Ménière’s Disease Patients

Jul 28, 2016

Rhythm Announces “The Genetic Obesity Project” to Expand Understanding of Rare Genetic Disorders of Obesity

Jul 28, 2016

Adaptimmune Receives Access to Priority Medicines (PRIME) Regulatory Support for its SPEAR® T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma

Jul 28, 2016

Unilife Announces New Leadership Team and Targeted Growth Strategy

Jul 28, 2016

ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2α Antagonist, for the Treatment of Preterm Labor

Jul 27, 2016

TigerText Earns Prestigious HITRUST CSF Certification

Jul 27, 2016

AVITIDE TO EXPAND AFFINITY SEPARATION DISCOVERY AND MANUFACTURING OPERATIONS

Jul 26, 2016

Adaptimmune Receives Orphan Drug Designation in the European Union for its NY-ESO SPEAR® T-cell Therapy for Treatment of Soft Tissue Sarcoma

Jul 25, 2016

Tricida Announces $55M Series C Financing

Jul 25, 2016

PROSPECTIVE MULTICENTER STUDY SHOWS REMARKABLE HEALING RATES WITH SONENDO’S GENTLEWAVE® SYSTEM

Jul 25, 2016

Nabriva Announces Nomination of Candidates for Its Supervisory Board

Jul 21, 2016

Study Demonstrates Cardiac Troponin Analysis Can Help Identify Heart Disease Risk and Guide Treatment

Jul 21, 2016

Galenica and Relypsa Announce Agreement for Galenica to Acquire Relypsa

Jul 20, 2016

Rhythm Announces New England Journal of Medicine Publication of Setmelanotide Phase 2 Data for Treatment of POMC Deficiency Obesity

Jul 20, 2016

Invitae introduces new Breast Cancer STAT Panel for patients with breast cancer who need rapid test results to guide surgical decisions

Jul 18, 2016

SI-BONE, Inc. Announces 40th Peer-Reviewed Publication - a Multicenter Long Term Outcomes Study Showing Durable Results With the iFuse Implant System®

Jul 18, 2016

Cynapsus Therapeutics Announces Positive Phase 3 Dose Titration Phase Results with APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease

Jul 13, 2016

Loxo Oncology Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-101

Jul 12, 2016

GC Aesthetics Raises $20 Million in Series D Financing

Jul 7, 2016

Aptuit LLC and Dimension Therapeutics Enter Strategic Partnership to Advance Select Dimension Programs Toward IND Filing

Jul 6, 2016

Merit Medical Acquires DFINE, Inc.

Jul 6, 2016

Intercept Pharmaceuticals Announces Closing of Public Offering of Convertible Senior Notes and Exercise in Full of Option to Purchase Additional Notes

Jul 5, 2016

Singulex enters into World-Wide Service Agreement with Tecan

Jun 30, 2016

Cynapsus Therapeutics Enrolls Last Patient in Pivotal Phase 3 Efficacy Trial of APL-130277 to Treat OFF Episodes in Patients with Parkinson’s Disease

Jun 29, 2016

argenx announces initial results from Phase 1 multiple ascending dose (MAD) study of ARGX-113 in healthy volunteers

Jun 28, 2016

Results from Phase 2 Exploratory Clinical Study Support Continued Development of Ganaxolone in Fragile X Syndrome

Jun 28, 2016

Invitae contributes more than 10,000 additional genetic variants to the ClinVar project

Jun 27, 2016

Results of Pre-Specified Exploratory Analysis of Phase 3 OPAL-HK Study Evaluating Effects of Veltassa on Blood Pressure and Aldosterone Published in Kidney International

Jun 27, 2016

ViewRay Added to Russell 3000, Russell Global and Russell Microcap Indexes

Jun 22, 2016

Dimension Therapeutics Announces Recombinant DNA Advisory Committee’s Unanimous Approval of Phase 1/2 Study Protocol for DTX301, Lead Inherited Metabolic Disease (IMD) Product Candidate to Treat OTC Deficiency

Jun 21, 2016

"Positive Patient Outcomes Data on Inspire Therapy Highlighted at SLEEP 2016"

Jun 21, 2016

Graybug Vision Expands Executive Team with Appointments of Charles P. Semba, MD, and Ward M. Peterson, PhD

Jun 20, 2016

Nabriva Presents Data on Lefamulin at the American Society of Microbiology (ASM) Microbe 2016 Conference

Jun 20, 2016

SI-BONE, Inc. Closes $20 Million Round of Growth Financing Led by Arboretum Ventures

Jun 20, 2016

Adaptimmune Receives Positive Opinion for Orphan Drug Designation in the European Union for SPEAR™ T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma

Jun 17, 2016

Arsanis Presents Data at ASM Microbe 2016 Demonstrating Protection Against Multidrug-Resistant Escherichia coli and Klebsiella pneumoniae using Monoclonal Antibody Technology

Jun 17, 2016

ReViral Relocates

Jun 17, 2016

New laboratory facilities for ReViral

Jun 15, 2016

"Loxo Oncology Accepts Invitation to Present LOXO-101 to the FDA’s Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee"

Jun 15, 2016

Keystone Heart Ltd. Announces First Patient Enrolled in New Study to Protect the Brain During TAVR

Jun 13, 2016

"Alpine Immune Sciences Announces $48 Million Series A Financing to Support Discovery and Development of the Next Generation of Immunotherapies"

Jun 13, 2016

Aerpio Therapeutics Reports Peer-Reviewed Publication of Positive Clinical Results from the Phase 2a Study of Lead Candidate, AKB-9778, in Diabetic Macular Edema (DME): The TIME-2 Trial

Jun 13, 2016

Clementia Clinical Program: Next Step in Clementia’s Clinical Program for Fibrodysplasia Ossificans Progressiva (FOP)

Jun 11, 2016

True North’s Lead Product Candidate, TNT009, Demonstrates High Response Rates and Rapid Onset of Action in Interim Clinical Data in Patients with Cold Agglutinin Disease (CAD)

Jun 9, 2016

Otonomy Initiates Patient Enrollment in Single Phase 3 Clinical Trial of OTIPRIO™ in Patients with Acute Otitis Externa

Jun 9, 2016

argenx announces presentation of updated ARGX-110 phase 1 data in TCL at EHA 2016

Jun 8, 2016

Pieris Pharmaceutials Announces Closing of $16.5 Million Private Placement

Jun 7, 2016

Adimab and Innovent Expand Partnership for the Discovery of Antibodies and Bispecifics

Jun 7, 2016

Adimab and Innovent Expand Partnership for the Discovery of Antibodies and Bispecifics

Jun 7, 2016

Arvinas Publishes First Peer-Reviewed, In Vivo Data from its Proprietary PROTAC Technology

Jun 7, 2016

ObsEva Receives Clearance from US FDA to Initiate Phase 2b Study EDELWEISS with OBE2109, a Potentially Best-in-Class Oral GnRH Antagonist, for the Treatment of Endometriosis

Jun 7, 2016

Arvinas Publishes First Peer-Reviewed, In Vivo Data from its Proprietary PROTAC Technology

Jun 6, 2016

Seres Therapeutics Announces Research Collaboration with Mayo Clinic to Identify Microbiome Therapeutics for Primary Sclerosing Cholangitis, Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases

Jun 6, 2016

Principia Biopharma Announces Presentation of Initial Clinical Data on PRN1371 at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 6, 2016

ARMO BioSciences’ AM0010 Demonstrates Promising Clinical Data as an Immuno-oncology Monotherapy and in Combination with an Anti-PD-1 Checkpoint Inhibitor in Advanced Solid Tumors, Including Immune-Resistant Cancers

Jun 6, 2016

Invitae announces the launch of CancerCHECK to guide and support community oncologists through the hereditary cancer genetic testing process

Jun 5, 2016

Adaptimmune Announces Data from Clinical Studies of NY-ESO-1 SPEAR™ T-Cells in Multiple Cancers at the 2016 Annual American Society of Clinical Oncology (ASCO) Meeting

Jun 3, 2016

Pieris Pharmaceuticals Announces $16.5 Million Private Placement

Jun 3, 2016

Crizotinib Demonstrates Clinical Benefit in Phase II Study of East Asian Patients with ROS1-Positive Non-Small Cell Lung Cancer

Jun 2, 2016

argenx successfully closes €30 million private placement

Jun 2, 2016

argenx announces efficacy and expanded safety data from Phase 1 trial of ARGX-111

Jun 2, 2016

Publication of the LOCATION clinical study results in the renowned scientific journal of the European Atherosclerosis Society (EAS)

May 31, 2016

Singulex Announces a $50 Million Investment by Grifols for a 20% Stake in the Company

May 27, 2016

FDA Grants Accelerated Approval to Ocaliva™ (Obeticholic Acid) for the Treatment of Patients with PBC

May 26, 2016

Guardant Health Announces Project LUNAR, An Ambitious Multi-arm, Multi-site Umbrella Trial to Study Blood Test for Early Cancer Detection

May 26, 2016

Symbiomix Therapeutics Announces Positive Results from Phase 3 Trial of SYM-1219 for Bacterial Vaginosis, and Pre-NDA Meeting with FDA Supportive of 2016 NDA Filing

May 25, 2016

Relypsa Submits Supplemental New Drug Application to FDA Requesting Label Changes for Veltassa Based on Phase 1 Drug-Drug Interaction Studies

May 25, 2016

Good Start Genetics Announces Newest Launch of Next-Generation Embryo Screening Product

May 23, 2016

OrbiMed Closes Second Israel Venture Fund at $307M

May 23, 2016

OrbiMed doubles down on Israeli biotechs with $307M fund

May 23, 2016

OrbiMed Launches $307 Million Israel Venture Capital Fund

May 20, 2016

Otonomy Announces Assignment of C Code and Pass-Through Payment Status for OTIPRIO™

May 19, 2016

TriGuard Cerebral Protection Device Shows Reduction in Stroke Rate and Improvement in Patients’ Neurological Outcomes in TAVR Procedures

May 19, 2016

True North Therapeutics to Present Clinical Data in Patients with Cold Agglutinin Disease (CAD) for Lead Product Candidate TNT009

May 19, 2016

Selecta Biosciences Obtains Exclusive License to Proprietary Gene Therapy Vector from Massachusetts Eye and Ear

May 17, 2016

SI-BONE, Inc. Announces Publication of Second Multicenter Randomized Controlled Trial of the iFuse Implant System vs. Conservative Care in European Spine Journal

May 17, 2016

Loxo Oncology Announces the Closing of its Follow-On Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

May 11, 2016

Roka Bioscience Announces Extended On Board Stability for all Assays on the Atlas® System

May 11, 2016

Intellia Therapeutics Announces Closing of Initial Public Offering

May 7, 2016

Dimension Therapeutics Announces Preclinical Data from Bayer-Partnered Hemophilia A Program at American Society for Gene and Cell Therapy (ASGCT) Annual Meeting

May 4, 2016

Audentes Therapeutics and the University of Pennsylvania Announce Collaboration to Develop AAV Gene Therapy for Severe Liver Disease

May 2, 2016

A Healthy Prognosis For Some Stocks: Drugs and Robots

May 2, 2016

Graybug Vision GB-102 Toxicology/PK Study Presented at ARVO 2016

Apr 27, 2016

Adimab Announces Two New Partnerships and Commercial Licenses with Lilly, Kite and Jounce

Apr 27, 2016

Audentes Therapeutics Announces Presentation of Data at the American Society of Gene and Cell Therapy Annual Meeting

Apr 25, 2016

Vifor Fresenius Medical Care Renal Pharma and Relypsa Announce Submission of Marketing Authorization Application Requesting European Approval of Veltassa® for the Treatment of Hyperkalemia

Apr 22, 2016

Adaptimmune Announces SPEAR T-cells™ Brand for Proprietary Technology

Apr 21, 2016

"Affimed Presents Data on EGFRwt and EGFRvIII-targeting NK- and T-Cell TandAbs at the AACR Annual Meeting 2016"

Apr 21, 2016

"Affimed Presents Data on AFM13-mediated Innate/Adaptive Immune Crosstalk at the AACR Annual Meeting 2016"

Apr 20, 2016

ARMO BioSciences Announces AM0010 Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting in June 2016

Apr 20, 2016

SI-BONE, Inc. Announces Publication of Two-Year Results From a Prospective Multicenter Clinical Trial Showing Long-Term Clinical Benefits from SI Joint Fusion with the iFuse Implant System

Apr 20, 2016

argenx and AbbVie to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target

Apr 19, 2016

Corvus Pharmaceuticals Announces Results of Preclinical Studies Demonstrating Enhanced Immune Responses and Anti-Tumor Activity with CPI-444, an Investigational Immuno-Oncology Therapy

Apr 19, 2016

Loxo Oncology Announces First Pediatric Response to LOXO-101

Apr 18, 2016

Treatment with ViewRay’s MRI-Guided Radiation Therapy Now Available on the U.S. East Coast

Apr 18, 2016

Otonomy Announces Phase 3 Clinical Trial Plan for OTIPRIO™ in Otitis Externa Patients Based on Successful End-of-Phase 2 Review by FDA

Apr 18, 2016

"TigerText to Offer Secure Messaging Services to U.S. Cellular Customers "

Apr 18, 2016

Avedro Receives FDA Approval for Photrexa® Viscous, Photrexa® and the KXL® System for Corneal Cross-Linking

Apr 17, 2016

oxo Oncology TRK Inhibitor LOXO-101 Shows Durable Anti-Tumor Activity Across TRK Fusion Cancers in AACR Phase 1 Update

Apr 14, 2016

New Analyses of the Phase 3 POISE Trial of Ocaliva™ (Obeticholic Acid) for the Treatment of PBC Presented at EASL

Apr 13, 2016

Kala Pharmaceuticals Announces Closing of $68 Million Series C Financing

Apr 11, 2016

Regeneron and Intellia Therapeutics Announce Collaboration to Discover and Develop CRISPR/Cas Therapeutics

Apr 11, 2016

Nabriva Initiates Second Phase 3 Clinical Trial of Lefamulin (“LEAP 2”) in Patients with Community-Acquired Bacterial Pneumonia (CABP)

Apr 7, 2016

FDA Advisory Committee Unanimously Recommends Accelerated Approval of Ocaliva™ (obeticholic acid) for the Treatment of PBC

Apr 7, 2016

Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting AFP in Liver Cancer

Apr 6, 2016

Good Start Genetics Appoints Chief Executive Officer

Apr 6, 2016

Aeglea BioTherapeutics Announces Pricing of Initial Public Offering

Apr 4, 2016

Cynapsus Therapeutics and MonoSol Rx Announce Global IP Licensing Agreement

Apr 3, 2016

FDA grants orphan drug status to ganaxolone for pediatric female epilepsy

Mar 30, 2016

ReViral Scientific Advisory Board meeting

Mar 30, 2016

U.S. Food and Drug Administration Grants Orphan Drug Designation to Adaptimmune’s T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma

Mar 29, 2016

Invitae announces major expansion of its test menu for neurological, pediatric, and rare genetic conditions and introduces new panels for inherited metabolic disorders and newborn screening confirmation

Mar 28, 2016

SONENDO® RECEIVES FDA 510(K) CLEARANCE FOR THE NEXT GENERATION OF THE GENTLEWAVE® SYSTEM

Mar 24, 2016

First MRIdian System Installed in Europe at VU University Medical Center of Amsterdam

Mar 23, 2016

Synlogic Appoints an Industry Leader Nick Leschly to its Board of Directors

Mar 23, 2016

Otonomy Initiates Patient Enrollment in Second Phase 3 Clinical Trial of OTO-104 in Ménière’s Disease

Mar 22, 2016

Acutus Medical Completes $75 Million Series C Financing

Mar 22, 2016

Corvus Announces Pricing of Initial Public Offering

Mar 21, 2016

Blue Cross Blue Shield of Michigan Announces Positive Coverage Policy for iFuse Implant System® MIS SI Joint Fusion

Mar 17, 2016

Pieris Pharmaceuticals Announces Presentation of In Vivo Preclinical Data for Its Lead Bispecific Immuno-Oncology Drug Candidate, PRS-343, at the 2016 Annual Meeting of the American Association for Cancer Research (AACR)

Mar 17, 2016

Dimension Therapeutics Receives Positive Opinion for European Orphan Drug Designation for DTX301 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency

Mar 15, 2016

OrbiMed Advisors Offers 'One-Stop Shop' for Health-Care Companies

Mar 14, 2016

ProNAi Therapeutics Granted Orphan Drug Designation for PNT2258 for the Treatment of Diffuse Large B-Cell Lymphoma

Mar 14, 2016

Aeglea BioTherapeutics Announces FDA Acceptance of its Investigational New Drug Application for AEB1102 for the Treatment of Hematological Malignancies

Mar 9, 2016

Intellia Founders Awarded Distinguished Alpert Prize

Mar 3, 2016

Otonomy Initiates Phase 2 Clinical Trial of OTIPRIO™ in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes

Mar 2, 2016

Otonomy Announces Commercial Availability of OTIPRIO™

Feb 29, 2016

Clementia Announces Last Patient Enrolled in Phase 2 trial of Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva

Feb 25, 2016

True North Therapeutics Receives Orphan Drug Designation in the European Union for TNT009 for the Treatment of Autoimmune Hemolytic Anemia, including Cold Agglutinin Disease (CAD)

Feb 17, 2016

argenx opens clinical trial sites in South Korea for ARGX-111 program

Feb 17, 2016

Synlogic Secures $40 Million in Series B Financing

Feb 12, 2016

SI-BONE, Inc. Announces Medicare Administrative Contractor National Government Services, Inc. Establishes Positive Coverage for MIS SI Joint Fusion Effective April 1st, 2016

Feb 10, 2016

ARMO BioSciences Raises $50 Million Series C Financing

Feb 9, 2016

Seres Therapeutics Announces Publication of Positive SER-109 Phase 1b/2 Study Results in The Journal of Infectious Diseases

Feb 9, 2016

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Adaptimmune’s Affinity Enhanced T-cell Therapy Targeting NY-ESO in Synovial Sarcoma

Feb 8, 2016

Sientra® Announces Return of All Products to U.S. Market

Feb 4, 2016

Cerapedics Announces Publication of Results from Pivotal IDE Clinical Trial of i-FACTOR™ Bone Graft in the Cervical Spine

Feb 2, 2016

argenx receives milestone payment in LEO Pharma collaboration

Feb 2, 2016

Adaptimmune and GSK expand Strategic Immunotherapy Collaboration

Feb 1, 2016

GLAUKOS LAUNCHES NEW DIRECT SALES ORGANIZATION AND BEGINS COMMERCIALIZATION OF ISTENT INJECT® TRABECULAR MICRO-BYPASS STENT IN CANADA

Feb 1, 2016

argenx receives milestone payment in LEO Pharma collaboration

Feb 1, 2016

"Good Start Genetics’ Cost Effectiveness Study Demonstrates Clinical Outcomes

Feb 1, 2016

Aduro Biotech Receives $22.4 Million in Clinical Development Milestone Payments From Janssen

Jan 28, 2016

Catalent Biologics And Cerenis Therapeutics Announce Phase III Trial Of CER-001 In Europe And North America Leveraging GPEx® Cell Line Technology

Jan 27, 2016

OrbiMed launches immune-cell therapy company Adicet with a $51mm series A round

Jan 26, 2016

Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss

Jan 25, 2016

Relypsa Announces Results From Veltassa Drug-Drug Interaction Studies in Healthy Volunteers

Jan 25, 2016

Affirmed Enters into Collaboration with Merck to Evaluate AFM13 in Combination with KEYTRUDA (pembrolizumab) for Patients with Hodgkin Lymphoma

Jan 20, 2016

INTERNATIONAL STUDY SHOWS 3-YEAR BENEFITS OF GLAUKOS ISTENT® TRABECULAR MICRO-BYPASS STENT IN COMBINATION WITH CATARACT SURGERY

Jan 20, 2016

SI-BONE, Inc. Announces European Expansion with Formation of SI-BONE UK Ltd and Key Additions to Management Team

Jan 19, 2016

argenx announces € 16 M investment by US funds advised by subsidiaries of Federated Investors

Jan 19, 2016

ACORDA ANNOUNCES A RECOMMENDED CASH TENDER OFFER FOR ALL SHARES, ADSs AND OTHER EQUITY INSTRUMENTS IN BIOTIE

Jan 15, 2016

Loxo Oncology Announces EMA Orphan Drug Designation Granted to LOXO-101 for Treatment of Soft Tissue Sarcoma

Jan 14, 2016

Practice Fusion Accelerates Revenue Growth and Adds 5,000 New Active Practices in 2015

Jan 12, 2016

Intellia Therapeutics Launches New Division to Accelerate Ex Vivo Programs with CRISPR/CAS9

Jan 12, 2016

Tricida Announces FDA Acceptance of Investigational New Drug Application for Lead Candidate TRC101 and Hiring of Claire Lockey as Chief Development Officer and Edward J. Hejlek as General Counsel

Jan 12, 2016

Otonomy Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 12, 2016

Adimab Announces Technology Transfer Agreement with Merck

Jan 11, 2016

Adimab Provides Update on Recent Partnerships and Milestones

Jan 11, 2016

Helix Expands Ecosystem for Consumer Genomics Through Two New Partnerships

Jan 11, 2016

Seres Therapeutics Announces Strategic Collaboration with Nestlé Health Science for Microbiome-Based Clostridium Difficile and Inflammatory Bowel Disease Therapies in Markets Outside of North America

Jan 8, 2016

Invitae announces it met volume guidance by delivering nearly 19,000 billable tests in 2015 and sets volume guidance at 50,000-70,000 billable tests for 2016

Jan 7, 2016

Adaptimmune Expands T-cell Engineering Expertise to Develop Affinity Enhanced T-cell Therapies for Autoimmune Indications

Jan 7, 2016

Cynapsus and Michael J. Fox Foundation Collaborate on Pilot Use of Wearable Device and Data Science Approaches in Phase 3 Parkinson’s Clinical Study

Jan 7, 2016

Rhythm Receives Orphan Drug Designation for Setmelanotide for the Treatment of Prader-Willi Syndrome

Jan 7, 2016

Alector Announces Closing of Series D Financing – Total Capital Raised in 2015 Exceeds $60M

Jan 7, 2016

Principia Biopharma Advances BTK Inhibitor Program in Autoimmune Disease and FGFR Inhibitor Program in Oncology

Jan 7, 2016

GLAUKOS WILL BEGIN PHASE II CLINICAL TRIAL FOR IDOSE™ TRAVOPROST INTRAOCULAR IMPLANT IN GLAUCOMA PATIENTS

Jan 7, 2016

Dimension Therapeutics Announces Initiation of Phase 1/2 Study for DTX101 for the Treatment of Hemophilia B

Jan 7, 2016

Rhythm Receives FDA Breakthrough Therapy Designation for Setmelanotide for Treatment of POMC Deficiency Obesity

Jan 7, 2016

"Aeglea BioTherapeutics Announces FDA Acceptance of its

Jan 6, 2016

Sage Therapeutics Announces Pricing of Public Offering of Common Stock

Jan 5, 2016

argenx announces initial results from a Phase 1 single ascending dose study of ARGX-113 in healthy volunteers

Jan 5, 2016

Aduro Biotech Expands Patent Portfolio With Key Newly Issued Composition and Methods Patents

Jan 1, 2016

Dr Elaine Thomas joins the ReViral team as Head of Virology

Dec 23, 2015

Avedro Announces CE Mark Clearance for its Mosaic Advanced Cross‐Linking System and CEO Transition

Dec 23, 2015

Selecta Biosciences Announces Dosing of First Patient in Phase 1b Clinical Trial for SEL-212

Dec 22, 2015

Loxo Oncology Announces First Patient Enrolled in Phase 1 Trial of LOXO-101 in Pediatric Cancer Patients

Dec 21, 2015

OrbiMed Launches $950 Million Venture Capital Fund

Dec 21, 2015

SI-BONE, Inc. Announces Medicare Administrative Contractor CGS Administrators, LLC Establishes Positive Coverage for MIS SI Joint Fusion Effective February 1st, 2016

Dec 21, 2015

Relypsa Announces Veltassa™ is Now Available in the United States for the Treatment of Hyperkalemia

Dec 21, 2015

Guardant Health And Mirati Therapeutics Enter Into Collaboration On Glesatinib (MGCD265) In Non Small Cell Lung Cancer (NSCLC) Trial

Dec 21, 2015

Aduro Biotech Announces Initiation of Phase 1 Study of ADU-741 for the Treatment of Prostate Cancer

Dec 21, 2015

Mirati Therapeutics Initiates Glesatinib (MGCD265) Phase 2 Trial In Non-Small Cell Lung Cancer (NSCLC)

Dec 21, 2015

Foundation Medicine And Mirati Therapeutics Collaborate To Develop A Companion Diagnostic For Glesatinib (MGCD265) In Non-Small Cell Lung Cancer (NSCLC)

Dec 18, 2015

ProNAi Therapeutics Added to NASDAQ Biotechnology Index

Dec 17, 2015

The Year's Best VC Deal Was for a Company You've Never Heard Of

Dec 17, 2015

"Cerenis Therapeutics admitted to the SRD (Defered Settlement Service) “Long-only”"

Dec 17, 2015

Mirati Therapeutics Doses First Patient In Expansion Cohorts Of MGCD516 Phase 1b Trial In Genetically Selected Patients

Dec 17, 2015

Adaptimmune Announces Initiation of Study to Evaluate its New Affinity Enhanced T-Cell Therapy Targeting MAGE-A10 in Patients with NSCLC, the Most Common Form of Lung Cancer

Dec 17, 2015

FDA Extends PDUFA Date for Obeticholic Acid for the Treatment of PBC

Dec 16, 2015

Marinus Pharmaceuticals Completes Patient Recruitment in Phase 3 Clinical Trial of Ganaxolone in Focal Onset Seizures

Dec 16, 2015

Aduro Biotech Receives Milestone Payment From Janssen for Acceptance of Investigational New Drug Application for ADU-741 in Prostate Cancer

Dec 15, 2015

Otonomy Added to NASDAQ Biotechnology Index

Dec 15, 2015

INTERNATIONAL STUDY DEMONSTRATES POTENTIAL FOR TITRATABLE TREATMENT WITH 1, 2 OR 3 GLAUKOS ISTENT® TRABECULAR MICRO-BYPASS STENTS IN OPEN-ANGLE GLAUCOMA PATIENTS

Dec 15, 2015

Commercial Launch of the Long SpineSTAR® Ablation Instrument

Dec 14, 2015

Affimed Added to NASDAQ Biotech Index

Dec 14, 2015

Seres Therapeutics Announces Initiation of a Phase 1b Clinical Trial of SER-287 in Mild-to-Moderate Ulcerative Colitis

Dec 14, 2015

Aduro Biotech Receives Orphan Drug Designation in the European Union for CRS-207 and GVAX Pancreas for the Treatment of Pancreatic Cancer

Dec 11, 2015

Otonomy Announces FDA Approval of OTIPRIO(TM) for the Treatment of Pediatric Patients Undergoing Tympanostomy Tube Placement Surgery

Dec 10, 2015

Cynapsus Announces Successful Completion of Bioavailability and Pharmacokinetic Study and Provides Update on European Clinical Plans

Dec 10, 2015

Aduro Biotech Announces First Patient Dosed in Phase 1 Study of ADU-214 for the Treatment of Lung Cancer

Dec 9, 2015

Clementia Clinical Program: Clementia Natural History Study and Phase 2 Clinical Trial Enrollment Update

Dec 8, 2015

Adimab Establishes Antibody Discovery Collaborations with MD Anderson and Memorial Sloan Kettering

Dec 8, 2015

Pieris Pharmaceuticals Announces First Cancer Immunotherapy Collaboration

Dec 8, 2015

Cynapsus Therapeutics Announces Positive Data Presentations at World Congress on Parkinson’s Disease and Related Disorders Meeting

Dec 7, 2015

Pieris Pharmaceuticals Presents Clinical Data for Its Hepcidin Antagonist Program, PRS-080, at the 2015 American Society of Hematology (Ash) Annual Meeting

Dec 7, 2015

Marinus Presents Additional Responder Analysis Data for Ganaxolone in Focal Onset Seizures at the American Epilepsy Society Annual Meeting

Dec 7, 2015

True North Therapeutics Presents Data in Patients with Cold Agglutinin Disease (CAD) Supporting Patient Profiles for TNT009 Phase 1b Study

Dec 6, 2015

Affimed Presents Data Comparing T-cell- and NK-cell-engaging TandAbs AFM11 and AFM12 at AS

Dec 6, 2015

Affimed Presents Additional Data on Combination of AFM13 with Checkpoint Inhibitors at ASH

Dec 4, 2015

argenx to host workshop and webcast announcing topline clinical TCL data and preclinical AML data from ARGX-110 program

Dec 3, 2015

True North Therapeutics Announces $40 Million Series C Financing

Dec 3, 2015

Arvinas Presents Data at the 2015 ASH Annual Meeting

Dec 3, 2015

Targeting Protein Homeostasis Holds Potential to Treat Solid Tumors and Blood Cancers

Dec 2, 2015

ORIC Pharmaceuticals Announces $53 Million Series B Financing to Support Discovery and Development of Novel Therapies for Treatment-Resistant Cancers

Dec 2, 2015

InspireMD Receives EU Regulatory Approval for Additional Supplier of CGuardTM Delivery Catheters

Dec 1, 2015

Otonomy Completes Enrollment in OTIPRIO(TM) Phase 2 Trial and Demonstrates Clinical Feasibility in Patients With Acute Otitis Externa

Dec 1, 2015

Adaptimmune and Universal Cells announce Collaboration to Develop Allogeneic T-Cell Therapies

Nov 30, 2015

Intercept Pharmaceuticals Initiates Phase 1 Study of INT-767, a Dual FXR and TGR5 Agonist

Nov 30, 2015

Pieris Pharmaceuticals Achieves Payment Milestone in Sanofi Collaboration

Nov 24, 2015

At 3 Years, Inspire Upper Airway Stimulation Therapy Shows Significant Sustained Reductions in Sleep Apnea Severity

Nov 24, 2015

Adaptimmune Initiates Phase I / II trial Evaluating its Affinity Enhanced T-Cell Therapy Targeting

Nov 24, 2015

Aduro Biotech Confirms All Clinical Trials Continue Unaltered and as Planned

Nov 23, 2015

Arsanis Initiates Phase 1 Study of Lead Product Candidate ASN100

Nov 23, 2015

ObsEva Closes CHF 60 (USD 60) Million in Series B Financing

Nov 23, 2015

Aduro Biotech Receives Orphan Drug Designation in the European Union for CRS-207 for the Treatment of Mesothelioma

Nov 23, 2015

Cerapedics: A PMA First Opens New Opportunities in Cervical Spine Osteobiologics

Nov 20, 2015

ObsEva and Kissei Pharmaceutical Announce Global Agreement to Develop and Commercialize KLH-2109 for the Treatment of Endometriosis

Nov 20, 2015

InspireMD Announces Positive Twelve Month Follow-Up CARENET Trial Data at VEITH Symposium 2015

Nov 19, 2015

GLAUKOS SUBMITS IND APPLICATION TO FDA TO STUDY IDOSETM TRAVOPROST INTRAOCULAR IMPLANT IN GLAUCOMA PATIENTS

Nov 19, 2015

Pieris Pharmaceuticals Collaborator Daiichi Sankyo Doses First Subject in a Phase 1 Clinical Study for Lead Partnered Anticalin Program

Nov 18, 2015

Invitae announces expansion of hereditary cancer testing menu

Nov 18, 2015

Aduro Biotech Receives Milestone Payment From Janssen for Submission of Investigational New Drug Application for ADU-741 in Prostate Cancer

Nov 17, 2015

Aerpio Therapeutics Reports Positive Clinical Results from the Phase 2a Study of Lead Candidate, AKB-9778, in Diabetic Macular Edema (DME): The TIME-2 Trial

Nov 17, 2015

Loxo Oncology Announces the Closing of Its Follow-On Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Nov 14, 2015

Intercept Presents New Data Analyses on Non-Invasive Liver Testing From FLINT Trial of Obeticholic Acid in Nonalcoholic Steatohepatitis at AASLD 2015

Nov 14, 2015

Intercept Presents New PBC Data at AASLD 2015

Nov 12, 2015

Avedro Completes New $32 Million Round of Financing

Nov 12, 2015

Practice Fusion Announces Appointment of Tom Langan as Permanent Chief Executive Officer

Nov 12, 2015

US Patent Awarded to Singulex for Expanded Use of Biomarkers Troponin I and T to Detect Cardiac Health Status with Single-Molecule Methods

Nov 11, 2015

TigerText Closes on $50 Million in Financing to Accelerate Growth; Launches TigerText Anywhere Initiative

Nov 11, 2015

Loxo Oncology Prices Follow-On Offering of Common Stock

Nov 9, 2015

SI-BONE, Inc.® Announces iFuse Implant System® Receives Indication Cleared by the FDA that Includes Improved Pain, Patient Function and Quality of Life at 12-Months

Nov 9, 2015

Clementia Phase 2 Clinical Trial Site in London, UK Now Enrolling Children

Nov 6, 2015

Rhythm Presents Positive Data from Phase 1b Study of Setmelanotide for the Treatment of Genetic Obesity

Nov 5, 2015

Adaptimmune Announces Data from Clinical Study of NY-ESO Affinity Enhanced T-Cell Therapy in Synovial Sarcoma at the 2015 Annual Meeting of SITC

Nov 5, 2015

Pieris Pharmaceuticals Announces Presentation of Clinical Data for Its Hepcidin Antagonist Program, PRS-080, at the 2015 American Society of Hematology (ASH) Annual Meeting

Nov 3, 2015

Cerapedics Receives FDA Approval for i-FACTOR™ Peptide Enhanced Bone Graft in Cervical Spine Surgery

Nov 2, 2015

Bristol-Myers Squibb to Acquire Cardioxyl Pharmaceuticals, Inc.

Oct 30, 2015

ARMO BioSciences Presents Positive Phase 1 Trial Results of AM0010 at Upcoming Medical Conferences

Oct 29, 2015

ProNAi Initiates 'Brighton' Phase II Trial of PNT2258 in Patients with Richter's Transformation

Oct 29, 2015

Aduro Biotech Receives Milestone Payment From Janssen for Acceptance of Investigational New Drug Application for ADU-214 in Lung Cancer

Oct 28, 2015

Igenica Biotherapeutics Enters Into a Strategic Oncology Research Agreement with MedImmune

Oct 28, 2015

Aduro Biotech and Protein Potential Present Data Demonstrating Novel Vaccine Offers 100% Protection in Malarial Model

Oct 26, 2015

Loxo Oncology Announces Broad Pipeline Update at AACR-NCI-EORTC, Including New LOXO-101 Phase 1 Data

Oct 26, 2015

Corvus Pharmaceuticals Enters Clinical Trial Collaboration Agreement

Oct 26, 2015

"Aeglea BioTherapeutics Doses First Patient in Phase 1 Study of AEB1102 for Treatment of Solid Tumors

Oct 23, 2015

Igenica Biotherapeutics to Present New Data on Proprietary SNAP Antibody Drug Conjugate Technology at Upcoming World ADC Summit

Oct 22, 2015

arGEN-X Completes First Dosing of ARGX-113 for Severe Autoimmune Disorders

Oct 21, 2015

Dimension Therapeutics Announces Pricing of Initial Public Offering

Oct 21, 2015

RELYPSA ANNOUNCES FDA APPROVAL OF VELTASSA(TM) (PATIROMER) FOR ORAL SUSPENSION FOR THE TREATMENT OF HYPERKALEMIA

Oct 21, 2015

Arvinas Secures $41.6M Series B Financing – Appoints New Board Members

Oct 18, 2015

ViewRay® Receives Regulatory Approval to Sell MRI-Guided Radiation Therapy System in Korea

Oct 15, 2015

Open Monoclonal Technology and ARMO BioSciences Announce Anti-PD1 Antibody and OmniAbTM Platform License Agreement

Oct 14, 2015

Loxo Oncology Announces First Patient Enrolled in LOXO-101 Phase 2 Basket Trial in Patients With Solid Tumors Harboring TRK Fusions

Oct 13, 2015

ViewRay® Receives 2015 Frost & Sullivan Technology Innovation Leadership Award

Oct 13, 2015

European Journal of Heart Failure Publishes Pre-Specified Sub-Group Analysis of Heart Failure Patients With Hyperkalemia From Phase 3 Trial of Patiromer FOS

Oct 13, 2015

Audentes Therapeutics Raises $65 Million In Series C Financing

Oct 13, 2015

Good Start Genetics Establishes National Relationship with UnitedHealthcare

Oct 9, 2015

Aerpio Therapeutics to Present TIME-2 Phase 2a Study of AKB-9778 in Diabetic Macular Edema Data at 2015 American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day

Oct 8, 2015

Aduro Biotech Receives Milestone Payment From Janssen for Submission of Investigational New Drug Application for ADU-214 in Lung Cancer

Oct 8, 2015

Clementia Clinical Program Update: Clementia Phase 2 Clinical Trial Site in Paris, France Now Enrolling Children

Oct 7, 2015

Invitae expands test menu to include hundreds of new genes, dozens of new test panels for cancer, cardiology, neuromuscular, pediatrics, and rare disorders

Oct 6, 2015

Acutus Medical’s AcQMap™ High Resolution Imaging and Mapping System Provides High Resolution Cardiac Mapping Combined with Exceptional Accuracy in Ultrasound Chamber Reconstruction in Patients with Atrial Fibrillation

Oct 6, 2015

SAGE Announces Initiation of Phase 1 and First Dosing of SAGE-217

Oct 5, 2015

Otonomy Receives FDA Clearance of Investigational New Drug Application for Tinnitus Product Candidate, OTO-311

Oct 1, 2015

Arvinas Inks Strategic License Agreement with Genentech

Sep 30, 2015

FierceBiotech names Arvinas as one of its “Fierce 15” Biotech Companies of 2015

Sep 30, 2015

FierceBiotech names Intellia Therapeutics as one of its “Fierce 15” Biotech Companies of 2015

Sep 30, 2015

Nabriva Therapeutics Announces Exercise of Over-Allotment Option

Sep 30, 2015

FierceBiotech’s 2015 Fierce 15 – Alector

Sep 30, 2015

Positive Data Presented on Pieris Pharmaceuticals' Inhaled Asthma Program at ERS and Company Strengthens Management Team

Sep 29, 2015

Good Start Genetics Announces EmbryVu

Sep 28, 2015

Palovarotene Phase 2 Study Milestone

Sep 28, 2015

Intercept Pharmaceuticals Announces Initiation of REGENERATE Trial for Obeticholic Acid in NASH Patients With Advanced Liver Fibrosis

Sep 28, 2015

Mirati Therapeutics Presents Interim Clinical Data From Ongoing MGCD516 Phase 1 Dose Escalation Study In Patients With Advanced Solid Tumors

Sep 26, 2015

Aduro Biotech Announces Phase 1b Mesothelioma Trial Featured in Spotlight Poster at ESMO/ECC

Sep 24, 2015

Otonomy to Present Results for AuriPro(TM) Phase 3 and OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting

Sep 24, 2015

FDA Office of Orphan Products Development Awards Rhythm $1 Million Grant to Support Phase 2 Study of Setmelanotide in Prader-Willi Syndrome

Sep 24, 2015

Aduro Biotech Enters Into Definitive Agreement to Acquire Premier Antibody Portfolio and Engineering Capabilities Through Purchase of BioNovion

Sep 23, 2015

Nabriva Therapeutics Announces Closing of Its Initial Public Offerin

Sep 23, 2015

arGEN-X’ Partner RuiYi, Inc. Announces First Human Dosing of Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6

Sep 21, 2015

Symbiomix Therapeutics Presents Data at ICAAC/ICC Demonstrating Oral Pharmacokinetics of Lead Product SYM-1219 Administered With and Without Food

Sep 21, 2015

Pieris Pharmaceuticals Presents Positive Preclinical Data on Lead Bispecific Immuno-Oncology Program

Sep 17, 2015

Dimension Therapeutics Announces FDA Fast Track Designation for Lead Candidate DTX101 in Patients with Hemophilia B

Sep 17, 2015

"Cerenis Therapeutics is joining the Euronext indexes CAC Small, CAC

Sep 17, 2015

Corvus Pharmaceuticals Completes $75 Million Series B Financing

Sep 16, 2015

Google, OrbiMed buy into Alector’s novel take on Alzheimer’s with a $32M round

Sep 15, 2015

ViewRay® Announces First International MRIdian® Installation at Seoul National University Hospital

Sep 15, 2015

Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock

Aug 24, 2015

SI-BONE, Inc. Announces Three Significant Clinical Evidence Publications on iFuse Implant System® for MIS SI Joint Fusion

Aug 21, 2015

Seres Therapeutics, Inc. Announces FDA Orphan Drug Designation for SER-109 for the Prevention of Recurrent Clostridium Difficile Infection in Adults

Aug 19, 2015

Arsanis Appoints Rene Russo to Executive Team; Strengthens Board of Directors with Industry Veterans Amy Schulman and Dan Burgess

Aug 19, 2015

ViewRay® (VRAY) Completes Private Placement, Raises Aggregate of $29.4 Million

Aug 18, 2015

Pieris Pharmaceuticals Appoints Louis A. Matis, M.D., as Chief Development Officer

Aug 17, 2015

SAGE Announces First Patient Treated in Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus

Aug 14, 2015

Practice Fusion Announces CEO Transition

Aug 13, 2015

Announcing TigerText for Apple Watch in iOS 5.3

Aug 13, 2015

Practice Fusion Partners with Stanford University to Help Discover Common Acid Reflux Drugs Potentially Associated with Increased Risk of Heart Attack

Aug 13, 2015

Invitae and collaborators announce publication of new data showing the clinical actionability of multi-gene panel testing for hereditary breast and ovarian cancer risk in JAMA Oncology

Aug 11, 2015

Dimension Therapeutics Expands Its Board of Directors with the Elections of Industry Leaders

Aug 10, 2015

Relypsa and Vifor Fresenius Medical Care Renal Pharma Enter Into Partnership to Commercialize Patiromer FOS in Europe and Additional Territories

Aug 10, 2015

Aduro Biotech Completes Enrollment in Phase 1b Clinical Trial of CRS-207 Immunotherapy for the Treatment of Mesothelioma

Aug 10, 2015

Relypsa Enters Two-Year Detailing Agreement With Sanofi in the United States

Aug 10, 2015

Health Canada Approves the Glaukos iStent Inject®

Aug 7, 2015

Symbiomix Therapeutics’ First Pivotal Trial Results for SYM-1219 for Bacterial Vaginosis Presented at IDSOG

Aug 6, 2015

GLAUKOS CORPORATION ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN U.S. PIVOTAL CLINICAL TRIAL FOR ISTENT INJECT®

Aug 6, 2015

SAGE Receives Special Protocol Assessment for Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus

Aug 6, 2015

Dimension Therapeutics Further Expands Leadership Team; Appoints Accomplished Industry Leader Jean M. Franchi as Chief Financial Officer

Aug 6, 2015

Avitide Secures Series C Financing to Expand On-Demand Biopharmaceutical Affinity Purification Platform and Achieve Profitability

Aug 5, 2015

InspireMD Announces Distribution Partnership of its CGuardTM Embolic Prevention System with Penumbra, Inc.

Aug 5, 2015

Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer

Aug 5, 2015

SNS FIRE CONFERENCE NAMES TRUE NORTH THERAPEUTICS A 2015 FIRESTARTER COMPANY

Jul 30, 2015

Practice Fusion Expands Leadership Team and Board with Industry Veterans from Google, Amazon, WebMD, Quest Diagnostics, and Zendesk

Jul 30, 2015

GLAUKOS CORPORATION RECEIVES REGULATORY APPROVAL IN AUSTRALIA FOR ISTENT INJECT®

Jul 30, 2015

Loxo Oncology Appoints Industry Veteran Tim Mayleben to Board of Directors

Jul 30, 2015

Cleave Biosciences Granted Key U.S. Patent Covering CB-5083

Jul 30, 2015

arGEN-X and University of Bern enter into license agreement to develop ARGX-110-based combination therapies for treatment-resistant cancers

Jul 30, 2015

Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency

Jul 28, 2015

Pieris Pharmaceuticals Announces Closing of Over-Allotment Option in Public Offering of Common Stock

Jul 28, 2015

Otonomy Initiates Phase 2 Clinical Trial for AuriPro(TM) in Second Label Expansion Indication

Jul 27, 2015

University of Colorado Cancer Center and Loxo Oncology Announce Publication That Provides Clinical Validation For LOXO-101 Against TRK Fusion Cancer

Jul 23, 2015

ViewRay Completes Alternative Public Offering, Raises $26.7 Million

Jul 22, 2015

Invitae announces online publication of data comparing traditional and multi-gene panel testing for hereditary breast and ovarian cancer in The Journal of Molecular Diagnostics

Jul 21, 2015

Biotie announces start of tozadenant Phase 3 Study in Parkinson's disease

Jul 21, 2015

ProNAi Therapeutics Announces Closing of IPO and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jul 21, 2015

Intercept Pharmaceuticals Appoints Richard Kim as Senior Vice President, Commercial Head of U.S.

Jul 20, 2015

Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence, Clinical Activity and Tolerability in Clinical Study in Multiple Myeloma Patients

Jul 14, 2015

JAMA Publishes Long-Term Safety and Efficacy Results of Trial With Relypsa's Patiromer FOS Over One Year

Jul 13, 2015

Cleave Biosciences Receives Orphan Designation from FDA for CB-5083 for Treatment of Multiple Myeloma

Jul 10, 2015

EDWARDS LIFESCIENCES ENTERS INTO AGREEMENT TO ACQUIRE CARDIAQ

Jul 8, 2015

Aeglea Biotherapeutics Appoints Sandy Mahatme and Russell Cox to Board of Directors

Jul 8, 2015

Pieris to Receive Seventh Milestone Payment From Daiichi Sankyo Collaboration to Develop Anticalin(R) Therapeutics

Jul 7, 2015

InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award

Jul 6, 2015

Pieris Pharmaceuticals Closes Public Offering of Common Stock

Jul 2, 2015

Adaptimmune Announces FDA Acceptance of Investigational New Drug (IND) Application for MAGE-A10 T in Patients with Non-small Cell Lung Cancer

Jul 1, 2015

Former Pharmacyclics CEO Raises $33.5M Series A for Corvus Pharmaceuticals

Jul 1, 2015

Seres Therapeutics Announces Closing of Initial Public Offering

Jun 30, 2015

VIEWRAY SECURES UP TO $50M IN DEBT FINANCING FROM CRG

Jun 30, 2015

GLAUKOS CORPORATION ANNOUNCES CLOSING OF ITS INITIAL PUBLIC OFFERING

Jun 29, 2015

Aduro Biotech Announces Immunotherapy Regimen Successfully Passes Futility Analysis in Phase 2b ECLIPSE Trial in Metastatic Pancreatic Cancer

Jun 29, 2015

Cynapsus Therapeutics Enrolls First Patient in Pivotal Phase 3 Efficacy Study Evaluating Sublingual, Film Strip Delivery of Apomorphine to Turn Parkinson’s Disease Patients from the OFF to the ON State

Jun 29, 2015

Intercept Pharmaceuticals Submits Applications in the U.S. and Europe for Marketing Approval of Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis

Jun 25, 2015

Cynapsus Therapeutics’ APL-130277 Improved Parkinson’s Symptoms and Rapidly Turned Patients from OFF to ON in Data Presented at the International Congress of Parkinson's Disease and Movement Disorders

Jun 23, 2015

Cynapsus Therapeutics Inc. Closes US$72.5 Million Public Offering of Common Shares in the United States

Jun 23, 2015

CardiAQ™ Valve Technologies reports first-in-human percutaneous transfemoral, transseptal implantation with its second generation transcatheter bioprosthetic mitral heart valve

Jun 23, 2015

ProNAi Appoints Dr. Barbara Klencke as Chief Development Officer

Jun 23, 2015

Clementia Pharmaceuticals Raises U.S. $60 Million in Mezzanine Financing to Support Development of Palovarotene for Fibrodysplasia Ossificans Progressiva

Jun 18, 2015

Preliminary Phase I results of ARGX-110 in patients with T-cell lymphomas presented at ICML

Jun 18, 2015

Sikka Software Raises $10.5 Million Series C Round to Increase its Rapidly Expanding Share of Cloud-based Retail Healthcare

Jun 18, 2015

Practice Fusion is the Market Share Leader for Solo and Small Clinician Practices

Jun 18, 2015

Practice Fusion Launches Native iOS and Android Applications; Only Meaningful Use-Certified EHR Available on 3 Platforms: Desktop, iOS and Android

Jun 18, 2015

Selecta Biosciences' Synthetic Vaccine Particles Instrumental in Breakthrough Research on Mucosal Vaccines

Jun 18, 2015

ProNAi Appoints Dr. Nicole Onetto and Mr. Robert Pelzer to its Board of Directors

Jun 16, 2015

ProNAi Strengthens Leadership Team; Opens Vancouver Corporate Headquarters

Jun 16, 2015

Biotie Announces Closing of U.S. Public Offering and Conversion of Convertible Notes

Jun 15, 2015

Glaukos Corporation Announces Launch of Initial Public Offering

Jun 15, 2015

PRINCIPIA BIOPHARMA PRESENTS FULL PHASE 1 CLINICAL TRIAL RESULTS FOR PRN1008, A NOVEL REVERSIBLE COVALENT BTK INHIBITOR, SUPPORTING FURTHER CLINICAL DEVELOPMENT IN AUTOIMMUNE AND INFLAMMATORY DISEASES

Jun 15, 2015

Adimab Establishes New Collaboration with Kite Pharma for the Discovery of Antibodies for T-cell Therapies

Jun 12, 2015

ProNAi Therapeutics Files Registration Statement for Proposed Initial Public

Jun 12, 2015

Seres Therapeutics Receives FDA Breakthrough Therapy Designation for Its Lead Product Candidate, SER-109

Jun 12, 2015

Biotie Announces Exercise of Over-allotment Option

Jun 11, 2015

Biotie Announces Completion of Pricing of U.S. Public Offering of ADSs and Conversion of Convertible Notes

Jun 10, 2015

Selecta Biosciences Initiates Phase 1 Clinical Program of SEL-212, Designed As the First Non-Immunogenic Biologic Treatment for Gout

Jun 10, 2015

Pieris Pharmaceuticals Completes Dosing of Healthy Volunteers in Phase I Clinical Trial for Anticalin Program in Anemia

Jun 9, 2015

Symbiomix Therapeutics Doses First Patient in Confirmatory Phase 3 Pivotal Study of Lead Drug Candidate SYM-1219 for Bacterial Vaginosis

Jun 9, 2015

Cerenis Therapeutics announces new Board members

Jun 9, 2015

Cynapsus Therapeutics Inc. Announces Launch of Proposed Public Offering of Common Shares in the United States

Jun 9, 2015

SAGE Therapeutics Announces Positive Top-Line Data in Exploratory Trial of SAGE-547 in Postpartum Depression

Jun 8, 2015

Good Start Genetics Publishes Variant Database Validation Study

Jun 4, 2015

Cynapsus Therapeutics Announces Issuance of U.S. Patent Providing Broad Coverage for Sublingual Apomorphine

Jun 2, 2015

Aduro Biotech Appoints Liana Wu as Vice President of Commercial

Jun 1, 2015

ARMO BioSciences Announces Efficacy and Safety Data for Immuno-Oncology Program with Novel Mechanism of Action

Jun 1, 2015

SI-BONE, Inc. Announces iFuse MIS SI Joint Fusion Gains Support from North American Spine Society (NASS) with Positive Coverage Policy Recommendation

Jun 1, 2015

Invitae launches new patient pay price of $475 for its full menu of genetic tests

May 30, 2015

Adaptimmune Announces Data from Clinical Studies of NY-ESO-1 Specific T-Cells in Multiple Cancers at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting

May 30, 2015

Initial Data from Ongoing Expansion Study of MGCD265 Show Preliminary Evidence of Clinical Efficacy in Heavily Pretreated Non-Small Cell Lung Cancer (NSCLC) Patients with MET Gene Alterations

May 29, 2015

arGEN-X presents preliminary efficacy and expanded safety data from Phase I trial of ARGX-111 at ASCO

May 28, 2015

Clementia Advances Natural History Study of Patients with Fibrodysplasia Ossificans Progressiva

May 28, 2015

Chicago Cardiology Institute Deploys TigerText to Accelerate Clinician Response Times

May 26, 2015

SI-BONE, Inc. Appoints Laura Francis Chief Financial Officer and Closes Additional Round of Growth Capital

May 26, 2015

Cerenis Therapeutics featured prominently at the International Symposium on Atherosclerosis (IAS)

May 25, 2015

Biotie announces agreement with FDA on a Special Protocol Assessment for tozadenant Phase 3 study

May 21, 2015

Otonomy Reports Phase 2b Topline Data for OTO-104 in Meniere's Disease

May 21, 2015

Singulex Announces EMD Millipore to Acquire Exclusive Rights to Singulex’s Ultra-Sensitive Single Molecule Counting (SMCTM) Technology

May 21, 2015

arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditions

May 19, 2015

New Data Shows Advantages of Acutus Medical Dipole Density Heart Imaging and Mapping System Compared to Standard Voltage-based Mapping in Patients with Atrial Flutter

May 19, 2015

Intercept Pharmaceuticals Announces Pivotal Phase 3 Clinical Trial of Obeticholic Acid in NASH

May 19, 2015

Practice Fusion and the American Urological Association Collaborate to Launch Overactive Bladder Population Health Management Initiative

May 19, 2015

arGEN-X awarded €1.5 million IWT grant to advance the application of NHance Fc modifications in therapeutic antibodies

May 14, 2015

PIERIS PHARMACEUTICALS APPOINTS IMMUNO-ONCOLOGY EXPERT, HOLBROOK KOHRT, M.D., PH.D., TO SPEARHEAD IMMUNO-ONCOLOGY EFFORTS AND INITIATES RESEARCH COLLABORATION WITH LEADING CANCER RESEARCH CENTER

May 14, 2015

SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status Epilepticus

May 13, 2015

Selecta and Genethon Collaborate to Create Next Generation Gene Therapies Using Selecta’s Synthetic Vaccine Particle Platform

May 13, 2015

Glaukos CorporationFiles Registration Statement for

May 12, 2015

InspireMD’s CGuard™ Highlighted at Clinical Presentation at EuroPCR 2015 Conference

May 12, 2015

TigerText Joins the Box Assured App Ecosystem

May 11, 2015

Adaptimmune Announces Closing of Initial Public Offering

May 7, 2015

Aduro Biotech's Preclinical Results for Its STING-Targeted CDN Immuno-Oncology Platform Highlighted in Prestigious Peer-Reviewed Publications

May 7, 2015

Adimab Establishes New Partnership with Celgene for Discovery of Antibodies and Bispecifics for Next-Generation Therapeutics for Patients

May 7, 2015

Otonomy Completes Enrollment in Phase 2 Clinical Trial for AuriPro(TM) in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes

May 4, 2015

Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis

May 4, 2015

Sonendo Receives 510(k) FDA Clearance For Its Multisonic Ultracleaning System

May 4, 2015

SI-BONE, Inc. Announces Medicare Contractor Cahaba to issue positive coverage of MIS SI Joint Fusion

Apr 30, 2015

Singulex Announces Partnership with The Dutch Technology Foundation (STW) to Accelerate the Development of Clinical Biomarkers - See more at: http://www.singulex.com/singulex-press-releases/#sthash.DrsY2zSd.dpuf

Apr 29, 2015

Betting on China for new Drug Dev BrandVoice

Apr 28, 2015

Singulex Key Patent Granted in Japan for Detecting or Monitoring Cardiovascular Disease Using Proprietary Biomarkers - See more at: http://www.singulex.com/singulex-press-releases/#sthash.HjNUj8Xg.dpuf

Apr 28, 2015

Ascendis Pharma A/S Announces Results of Phase 1 Study of TransCon Treprostinil

Apr 28, 2015

Otonomy Announces FDA Acceptance of AuriPro(TM) New Drug Application

Apr 27, 2015

Otonomy Presents AuriPro(TM) Phase 3 Results at American Society of Pediatric Otolaryngology Conference

Apr 27, 2015

Invitae appoints Robert Nussbaum, M.D. as Chief Medical Officer

Apr 27, 2015

InspireMD Announces MGuard™ Prime Approval in Brazil

Apr 23, 2015

Dimension Therapeutics to Develop Gene Therapy Treatments for Patients with Ornithine Transcarbamylase (OTC) Deficiency and Glycogen Storage Disease Type Ia (GSDIa)

Apr 23, 2015

Intercept Announces New FLINT Trial Data Showing OCA Treatment Increases Fibrosis Resolution and Cirrhosis Prevention in High-Risk NASH Patients

Apr 23, 2015

arGEN-X Announces Publication on Therapeutic Potential of ARGX-115 in Cancer Immunotherapy

Apr 21, 2015

SAGE Therapeutics Announces Closing of $138 Million Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares

Apr 21, 2015

Dimension Therapeutics Secures $65 Million in Oversubscribed Series B Financing

Apr 21, 2015

Audentes Therapeutics Appoints Stephen Squinto, Ph.D. to its Board of Directors

Apr 21, 2015

Loxo Oncology’s LOXO-101 Demonstrates Encouraging Initial Results From Ongoing Phase 1a Dose Escalation Study

Apr 20, 2015

Aduro Biotech Announces Close of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Concurrent Private Placement

Apr 20, 2015

SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol to Evaluate SAGE-547 in Patients With Super-Refractory Status Epilepticus

Apr 20, 2015

Otonomy Completes Enrollment of OTO-104 Multiple-Dose Safety Study in Meniere's Disease Patients

Apr 14, 2015

TigerText Introduces First Secure Enterprise Messaging App for the Apple Watch

Apr 14, 2015

Aduro Biotech Announces Pricing of Its Initial Public Offering

Apr 14, 2015

arGEN-x N.V. Announces Changes to the Board of Directors

Apr 14, 2015

Practice Fusion and ePatientFinder Partner to Launch One of the Nation’s Largest EHR-Based Clinical Trial Networks

Apr 14, 2015

SAGE Therapeutics Announces Pricing of Public Offering of Common Stock

Apr 13, 2015

GOOD START GENETICS ENTERS EXCLUSIVE LICENSE AGREEMENT WITH

Apr 10, 2015

CardiAQ™ Valve Technologies receives FDA IDE Approval for a US Early Feasibility Study of Its Second-Generation Transfemoral and Transapical Transcatheter Mitral Valve Implantation Systems

Apr 9, 2015

Singulex Announces Collaboration with CHDI Foundation to Develop Biomarker Assays for Huntington’s Disease

Apr 9, 2015

arGEN-X Opens Expansion Cohort in Phase 1b Study of ARGX-111 in Patients with MET Amplified Cancers

Apr 8, 2015

Relypsa Presents New Data on the Importance of Renin-Angiotensin-Aldosterone-System Inhibitor (RAASi) Therapy in Patients With Cardio-Renal Comorbidities at the Academy of Managed Care Pharmacy's 27th Annual Meeting

Apr 7, 2015

Cerapedics Announces Closing of Loan and Equity Financing

Apr 7, 2015

Nabriva Announces Financing of up to $120M to Advance Clincial Development of New Class of Antibiotic

Apr 7, 2015

True North Therapeutics Announces $35 Million Series B Financing

Apr 7, 2015

Cerapedics Announces Closing of Loan and Equity Financing

Apr 6, 2015

Intercept Pharmaceuticals Announces Completion of Public Offering

Apr 2, 2015

Clementia Advances Phase 2 Clinical Trial of Palovarotene in Fibrodysplasia

Apr 2, 2015

SAGE Therapeutics Announces Positive End-of-Phase 2 Meeting With FDA and Planned Initiation of SAGE-547 Global Phase 3 Trial in Mid-2015

Apr 1, 2015

Otonomy Appoints Dean Hakanson, M.D., as Chief Medical Officer

Mar 30, 2015

PIERIS PHARMACEUTICALS AND THE UNIVERSITY OF MELBOURNE RECEIVE RESEARCH GRANT TO ADVANCE IMMUNOLOGICAL DISEASES PROGRAM

Mar 30, 2015

Aduro Biotech Establishes Major Collaboration with Novartis for Global Research, Development and Commercialization of Immuno-Oncology Products Derived from its Proprietary STING-Targeted CDN Platform Technology

Mar 26, 2015

Aduro Receives Orphan Drug Designation for CRS-207 in Mesothelioma

Mar 26, 2015

Invitae presents new data demonstrating use of next-generation sequencing for multi-gene panels at the 2015 American College of Medical Genetics Annual Clinical Genetics Meeting

Mar 26, 2015

PIERIS PHARMACEUTICALS REPORTS FULL-YEAR 2014 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Mar 26, 2015

Otonomy Initiates Phase 2 Clinical Trial for AuriPro(TM) in Label Expansion Indication

Mar 26, 2015

Relypsa Presents Sub-Group Analysis From Phase 3 Study of Patiromer FOS in Patients With Advanced Chronic Kidney Disease at 2015 National Kidney Foundation Spring Clinical Meeting

Mar 25, 2015

Practice Fusion Adds Medi-Span Drug Database to EHR Platform Impacting 4 Million e-Prescriptions a Month

Mar 24, 2015

SI-BONE, Inc. Adds SI Joint Specific Patent to IP Portfolio - Total U.S. Issued Patents now 16

Mar 23, 2015

Aeglea Biotherapeutics Raises $44 Million in Series B Financing

Mar 20, 2015

Intercept Announces New Data Analyses From FLINT Trial of Obeticholic Acid in NASH

Mar 20, 2015

Intercept Announces New Data Analyses From FLINT Trial of Obeticholic Acid in NASH

Mar 15, 2015

Data Presented at ACC Demonstrates Benefits of Keystone Heart’s TriGuard™ Cerebral Protection Device during TAVR

Mar 14, 2015

Relypsa Announces Phase 2 Data Showing Efficacy of Patiromer FOS in Heart Failure Patients With Chronic Kidney Disease at ACC Scientific Session

Mar 10, 2015

Adaptimmune appoints Lawrence M. Alleva to its Board of Directors

Mar 9, 2015

SI-BONE, Inc. Announces Publication of INSITE, a Prospective Multicenter Randomized Controlled Trial using iFuse Triangular Implants

Mar 4, 2015

Adaptimmune Strengthens Management Team with Key Executive Hires

Mar 4, 2015

Tricida Announces Closing of $30M Series B Financing

Mar 4, 2015

arGEN-X Expands Preclinical Pipeline with ARGX-115: A Novel Simple Antibody™ for Cancer Immunotherapy

Mar 3, 2015

TigerText Launches TigerConnect Secure Messaging Platform

Mar 3, 2015

Relypsa Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock

Mar 2, 2015

SI-BONE, Inc. Announces 15,000 iFuse Procedure Milestone

Mar 2, 2015

Loxo Oncology Announces 2015 Program Guidance and Reveals Selected Pipeline Programs

Feb 26, 2015

Otonomy Submits New Drug Application to the FDA for AuriPro™

Feb 18, 2015

Lonza and arGEN-X Announce a Multi-product GS Xceed™ License Agreement for Therapeutic Antibodies

Feb 18, 2015

Invitae announces completion of initial public offering and full exercise of underwriters’ option to purchase additional shares

Feb 18, 2015

TigerText Named to Verizon Partner Program

Feb 17, 2015

CoverMyMeds and Practice Fusion Partner to Bring Electronic Prior Authorizations for Medications to Over 110,000 of Practice Fusion’s Users

Feb 13, 2015

SAGE Therapeutics Appoints New Vice Presidents to Lead Key Organizational Functions

Feb 12, 2015

Practice Fusion Releases Online Check-In, eliminating the need for patients to fill out paper forms in the doctor’s office

Feb 9, 2015

Cerenis Therapeutics announces the appointment of a new Chief Medical Officer and new Board Members

Feb 5, 2015

Clementia Completes Enrollment Of First Cohort In Phase 2 Clinical Trial

Feb 4, 2015

Implementing the GentleWave™ System by Sonendo®

Feb 4, 2015

Intercept Pharmaceuticals Announces Pricing of Public Offering

Feb 3, 2015

Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 3, 2015

VIEWRAY RECEIVES FIRST EUROPEAN ORDER FOR ITS MRIDIAN SYSTEM

Feb 2, 2015

OrbiMed Launches $924 Million Royalty Credit Opportunities Fund

Feb 2, 2015

Ascendis Pharma A/S Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Feb 2, 2015

Ascendis Pharma A/S Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Jan 29, 2015

Intercept Receives Breakthrough Therapy Designation From FDA for Obeticholic Acid for Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis

Jan 29, 2015

PMV Pharma Named An Innovative Startup of 2014 by BioEntrepreneur

Jan 28, 2015

Dimension Therapeutics Appoints Successful Biopharma Leader Mary Thistle as Chief Business Officer

Jan 28, 2015

Dimension Therapeutics Appoints Successful Biopharma Leader Mary Thistle as Chief Business Officer

Jan 28, 2015

Otonomy Announces Closing of Follow-on Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 26, 2015

Invitae announces settlement in lawsuit with Myriad Genetics

Jan 22, 2015

Relypsa Announces Helen Torley, M.B. Ch.B., M.R.C.P. Joins Board of Directors

Jan 14, 2015

Casa de la Luz Hospice Adopts TigerText to Speed Response Times

Jan 14, 2015

Ascendis Pharma A/S Announces Initiation of a Phase 1 Single Ascending Dose Study of TransCon Treprostinil

Jan 14, 2015

Practice Fusion Announces Positive Results of Population Health Vaccine Initiative Conducted in Collaboration with Merck

Jan 14, 2015

Cerapedics Receives CE Mark and TGA Listing for New i‐FACTOR™ Flex FR Biologic Bone Graft

Jan 13, 2015

Practice Fusion and OptimizeRx Partner to Help Providers Improve Patients’ Access and Adherence to Medication

Jan 13, 2015

Dr. Evan Chaney to present on Salmonella enterica Detection in Poultry Matrices at IPPE

Jan 13, 2015

ITOCHU NAMED THE EXCLUSIVE DISTRIBUTOR FOR VIEWRAY’S MRI-GUIDED RADIATION THERAPY SYSTEM IN JAPAN

Jan 12, 2015

SAGE Therapeutics Initiates Phase 2a Trial of SAGE-547 in Postpartum Depression

Jan 12, 2015

Principia Biopharma Appoints Roy Hardiman As Chief Business Officer And Lewis Shuster To Board Of Directors

Jan 12, 2015

Loxo Oncology Appoints Alan Fuhrman to Board of Directors

Jan 12, 2015

Practice Fusion Signs 120th Revenue-Generating Deal with a Radiology Partner for its Electronic Health Records (EHR) Platform to Become Largest Hub Connecting Imaging Centers and Providers in the U.S.

Jan 12, 2015

arGEN-X Launches Innovative Access Program

Jan 12, 2015

Clementia Pharmaceuticals Opens Clinical Trial Site in Europe for Phase 2 Study

Jan 9, 2015

Adimab Announces New Partnerships with Acceleron, Oncothyreon, Surface Oncology and Potenza

Jan 9, 2015

Invitae Corporation files registration statement for proposed initial public offering

Jan 9, 2015

Invitae Corporation files registration statement for proposed initial public offering

Jan 9, 2015

SAGE Therapeutics Reports Updated Data From Ongoing Clinical Trial and Emergency Use Program of SAGE-547 in Patients With Super-Refractory Status Epilepticus

Jan 8, 2015

Principia Biopharma Successfully Completes Phase 1 Clinical Trial Of PRN1008, A Novel Oral BTK Inhibitor For Autoimmune Diseases

Jan 8, 2015

Cleave Biosciences Initiates Phase 1 Clinical Trial of CB-5083 in Patients with Advanced Solid Tumors

Jan 7, 2015

ProNAi Initiates Phase II Trial of PNT2258 in Patients with Relapsed or Refractory

Jan 7, 2015

Mirati Therapeutics Doses First Patient in Phase 2 Study of Mocetinostat in Bladder Cancer Patients with Genetic Alterations of CREBBP and EP300

Jan 6, 2015

Mirati Therapeutics Doses First Patient in Investigator-Sponsored Phase 2 Study of Mocetinostat in Non-Hodgkin's Lymphoma

Jan 5, 2015

Clementia Pharmaceuticals Raises $10 Million In Extension Of Series A Financing To Support Development Of Palovarotene For Fop – Company Opens New Subsidiary To Serve U.S. Market

Jan 5, 2015

Relypsa Announces Assignment of October 21, 2015 PDUFA Date for New Drug Application for Patiromer for Oral Suspension

Jan 5, 2015

SI-BONE, Inc. Announces Medicare Noridian Reimbursing for MIS SI Joint Fusion

Dec 23, 2014

Mirati Therapeutics Doses First Patient in Expansion Cohorts of Phase 1b Trial of MGCD265 in Genetically Selected Patients

Dec 23, 2014

Selecta and Skolkovo Foundation Collaboration to Develop a Synthetic Vaccine Particle in the Field of Immuno-oncology

Sep 9, 2014

OrbiMed Advisors Raises $325M for Second Asia Health-Care Fund

Sep 4, 2014

Cleave Biosciences Initiates Phase 1 Clinical Trial of CB-5083 in Patients with Multiple Myeloma

Sep 4, 2014

Mirati Therapeutics Initiates Phase 1 Study of MGCD516 for Non-Small Cell Lung Cancer and Other Advanced Solid Tumors

Sep 3, 2014

Durata Therapeutics to Present Safety and Efficacy Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

Sep 3, 2014

Cerenis Appoints Dr. Richard C. Pasternak as Chairman

Sep 3, 2014

Cerenis Receives EMA Orphan Drug Designation for CER-001 for the Treatment of ApoA-I and ABCA-1 Deficiencies

Sep 3, 2014

Amarin to Present at the Rodman & Renshaw 2014 Global Investment Conference

Sep 2, 2014

Aerpio Therapeutics Announces Publication of Preclinical Data on AKB-9778 for Common Eye Diseases

Sep 2, 2014

Affimed Secures $29.7M in Private Financing from Current and New Investors

Aug 27, 2014

Civitas Therapeutics Files Registration Statement for Proposed Initial Public Offering

Aug 27, 2014

TigerText Growth Accelerates in First Half of 2014 as Message Volume Surges 750%

Aug 27, 2014

Singulex Announces Preview of the Sgx ClarityTM IVD System and Presentation of 10 Abstracts Demonstrating Single Molecule (SMCTM) Technology Performance in Cardiovascular Disease at 2014 ESC Congress

Aug 27, 2014

arGEN-X – Business Update and First Half 2014 Results

Aug 26, 2014

Practice Fusion Further Expands Executive Team with Chief Commercial Officer and VP of Pharmaceutical Partnerships Hires

Aug 25, 2014

Biodel Appoints Gary G. Gemignani as Chief Financial Officer

Aug 25, 2014

Civitas Therapeutics Secures $55 Million in Series C Financing

Aug 25, 2014

Practice Fusion and Vitals Partner to Bring Online Appointment Booking and Doctor Reviews to Millions of Americans

Aug 19, 2014

arGEN-X announces positive preclinical results for ARGX-113

Aug 13, 2014

Otonomy Announces Pricing of Initial Public Offering

Aug 12, 2014

Allan J. Collins, M.D., to join NxStage as Senior Medical Advisor

Aug 11, 2014

InspireMD to Announce Results of CGuard™CARENET Trial at the TCT Innovation Session on Late Breaking Early Human Clinical Studies

Aug 11, 2014

Intercept Pharmaceuticals Reports Second Quarter 2014 Financial Results and Provides Business Update

Aug 11, 2014

Biodel Reports Third Quarter Fiscal Year 2014 Financial Results

Aug 11, 2014

Biodel's Concentrated Insulin BIOD-531 Demonstrates Superior Glucose Control Following Standardized Meals Compared to Marketed Insulins in a Phase 2 Clinical Trial in Patients With Type 2 Diabetes

Aug 7, 2014

NxStage Reports Record Second Quarter 2014 Financial Results And Increases Full-Year Revenue Guidance

Aug 7, 2014

Durata Therapeutics Reports Second Quarter 2014 Financial Results

Aug 6, 2014

Practice Fusion Acquires Ringadoc

Aug 1, 2014

Loxo Oncology Announces Pricing of Initial Public Offering

Jul 31, 2014

Revolutionary Radiation Therapy System From Viewray Is Acquired By Sylvester Comprehensive Cancer Center At The University Of Miami

Jul 28, 2014

Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial for Heart Failure Drug CXL-1427

Jul 28, 2014

Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update

Jul 28, 2014

CIOsynergy Announces TigerText as Official Sponsor for its August 14th, 2014 CIOhealth Event

Jul 28, 2014

Biodel Enters Into $15 Million Equity Commitment With Lincoln Park Capital

Jul 25, 2014

Ferdinand Verdonck Elected to Affimed’s Supervisory Board

Jul 23, 2014

InspireMD Reports Financial Results for the Second Quarter Ended June 30, 2014

Jul 23, 2014

Singulex Highlights Development Progress With Ultrasensitive Sgx ClarityTM System at AACC 2014

Jul 22, 2014

SAGE Therapeutics Receives Fast Track Designation for Lead Compound SAGE-547 to Treat Status Epilepticus

Jul 21, 2014

Multi-Center Trial Shows Significant Pain Relief For Spine Cancer Patients Following Targeted Radiofrequency Ablation Treatment

Jul 18, 2014

Durata Therapeutics Announces the U.S. Launch of DALVANCE™

Jul 17, 2014

Roka Bioscience Announces Pricing of Initial Public Offering

Jul 17, 2014

Practice Fusion Signs 122 Partnership Deals with Health System, Hospital, Lab and Imaging Clients in 2014

Jul 17, 2014

SAGE Therapeutics Announces Pricing of Initial Public Offering

Jul 15, 2014

InspireMD Appoints Dr. James Barry as Chief Operating Officer

Jul 14, 2014

Acceleron Pharma Appoints Terrence C. Kearney to its Board of Directors

Jul 14, 2014

Clementia Pharmaceuticals Initiates Phase 2 Study Of Palovarotene In Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Jul 14, 2014

Anthera Pharmaceuticals Announces Acquisition of Sollpura® (liprotamase) for Exocrine Pancreatic Insufficiency From Eli Lilly and Company

Jul 14, 2014

Otonomy Files Registration Statement for Proposed Initial Public Offering

Jul 8, 2014

Otonomy Announces Positive Results from Two Phase 3 Trials of AuriPro™ in Pediatric Patients Undergoing Ear Tube Placement Surgery

Jul 8, 2014

InspireMD Announces Successful Completion of CGuardTM CARENET (CARotid Embolic protection study using microNET) Trial

Jul 7, 2014

CardiAQ™ Valve Technologies, Inc. announces that it has obtained a stay of further proceedings in Neovasc Inc.’s pending European patent application covering Transcatheter Mitral Valve Replacement

Jul 2, 2014

InspireMD Selected for Inclusion in the Russell Microcap Index

Jun 30, 2014

Mirati Therapeutics Added to Russell 2000 Index

Jun 25, 2014

Practice Fusion and Emdeon Team Up to Simplify Medical Claim Filings on Practice Fusion’s Electronic Health Record (EHR) Platform

Jun 23, 2014

Dimension Therapeutics and Bayer HealthCare Enter Collaboration to Develop Novel Gene Therapy for Hemophilia A

Jun 23, 2014

Dimension Therapeutics Raises $30M Financing

Jun 23, 2014

Anthera Pharmaceuticals Appoints Brian R. Mueller to Board of Directors

Jun 20, 2014

Adimab Announces 50th Therapeutic Program Under Its Funded Discovery Partnerships

Jun 17, 2014

Selecta Biosciences to Accelerate Program for Novel Dual Action Vaccine for Malaria with support from the Bill & Melinda Gates Foundation

Jun 17, 2014

Practice Fusion Expands Executive Bench, Adding Chief Financial Officer

Jun 17, 2014

Selecta Accelerates Immune Tolerance Therapeutics and Announces New Product Candidate, SEL-212, for Refractory and Tophaceous Gout

Jun 17, 2014

Selecta Biosciences Enters Into Exclusive License Agreement with 3SBio to Develop Drug Candidate to Treat Gout

Jun 17, 2014

Mirati Therapeutics Receives Orphan Drug Designation from U.S. Food & Drug Administration for Mocetinostat in Myelodysplastic Syndrome

Jun 16, 2014

Cleave presents poster at 2014 FASEB Ubiquitin and Cell Regulation Meeting

Jun 13, 2014

Anthera Pharmaceuticals Appoints Dr. Philip Sager to Board of Directors

Jun 12, 2014

Ambit Biosciences Announces Presentation Of Data From Clinical Investigations Of Quizartinib At The 19th Congress Of The European Hematology Association

Jun 11, 2014

Amarin Announces Publication of Case Study Results Describing Reductions in Multiple Lipid Parameters for Individual Hyperlipidemic Patients Switched to Vascepa®

Jun 11, 2014

BioLineRx Receives Notice of Allowance for US Patent Covering Novel Treatment for Celiac Disease

Jun 10, 2014

Biodel to Present Data on Ultra-Rapid-Acting Insulin and Glucagon Product Candidates at 2014 American Diabetes Association Scientific Sessions

Jun 10, 2014

arGEN-X and The Leukemia & Lymphoma Society Partner on the Development of ARGX-110 for the Treatment of Waldenström’s Macroglobulinemia

Jun 10, 2014

SAGE Therapeutics Appoints James M. Frates to the Company's Board of Directors

Jun 6, 2014

CardiAQ™ Valve Technologies files US Lawsuit against Neovasc

Jun 5, 2014

RedHill Biopharma Announces New RHB-104 Patent in Japan and Provides Update on Phase III Crohn’s Program

Jun 5, 2014

SAGE Therapeutics Presents Preliminary SAGE-547 Clinical Data at Epilepsy Pipeline Conference

Jun 4, 2014

Ambit Biosciences Announces Changes To Board Of Directors

Jun 4, 2014

arGEN-X enters long-term strategic alliance with Shire Pharmaceuticals in therapeutic antibodies

Jun 4, 2014

New England Journal of Medicine Publishes Data From Durata Therapeutics' Discover Program

Jun 3, 2014

Ambit Biosciences Announces Presentation of Data from Clinical Investigations of Quizartinib at the 2014 Annual Meeting of The American Society Of Clinical Oncology

Jun 2, 2014

Cerenis Reports Two Positive Phase II Studies for HDL Mimetic CER-001 at EAS

May 29, 2014

arGEN-X to present results of Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced cancer at ASCO

May 28, 2014

Intercept Announces that FDA Grants Fast Track Designation to Obeticholic Acid for the Treatment of Patients with Primary Biliary Cirrhosis

May 28, 2014

arGEN-X announces collaboration with Bayer to discover and develop therapeutic antibody candidates

May 27, 2014

Sonendo® Receives 510(k) FDA Clearance For Its Multisonic Ultracleaning System

May 23, 2014

FDA Approves Durata Therapeutics' DALVANCE(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Susceptible Gram-Positive Bacteria, Including MRSA, in Adults

May 22, 2014

RedHill Biopharma Announces FDA Clearance for Phase III Study with RHB-102 Planned to Commence in Q3/2014

May 21, 2014

Acceleron Announces New Interim Phase 2 Data on Sotatercept and ACE-536 to be Reported at Three Oral Presentations at the 19th Annual Congress of the European Hematology Association

May 21, 2014

Singulex Appoints Peter Heseltine, M.B., B.Ch., B.A.O., as Chief Medical Officer - See more at: http://www.singulex.com/singulex-press-releases/#sthash.S2NQx92W.dpuf

May 21, 2014

Practice Fusion Launches Nation’s Largest Real-Time Healthcare Database

May 21, 2014

RedHill Biopharma and IntelGenx Report Positive RHB-103 Bioavailability Study Results in Support of Planned European Marketing Application in Q3/2014

May 20, 2014

"CardiAQ™ Valve Technologies reports Successful First-in-Human Trans-Apical implantation of its Second Generation Transcatheter Mitral Valve"

May 20, 2014

Relypsa Announces Commercial Manufacturing Agreement With DSM Fine Chemicals

May 20, 2014

InspireMD to Showcase Embolic Systems with MicroNetTM Technology and Results from MASTER I Trial at EuroPCR Conference

May 20, 2014

Crown Bioscience to showcase progression in human surrogate trials at the 50th ASCO Annual Meeting

May 19, 2014

Audentes Therapeutics Announces Six Abstracts to be Presented at the American Society of Gene and Cell Therapy Meeting May 21-24, 2014

May 15, 2014

Keystone Heart Raises $14M in Series B Funding for Cerebral Protection Devices

May 15, 2014

Acceleron Pharma Reports First Quarter 2014 Financial Results

May 15, 2014

Inspire Medical Systems Raises $40 Million in Series E Funding

May 15, 2014

Crown Bioscience receives $26.55 million in Series D Funding

May 15, 2014

Mirati Therapeutics Reports First Quarter 2014 Financial Results and Provides Business Update

May 15, 2014

Amarin Announces Private Exchange Transactions Regarding Outstanding Senior Exchangeable Notes

May 15, 2014

Inspire Medical Systems Raises $40 Million in Series E Funding

May 14, 2014

New Janssen Labs Incubator Could Bring Up to 50 Companies to South SF

May 13, 2014

Anthera Pharmaceuticals Reports 2014 First Quarter Financial Results and Operational Update

May 13, 2014

Biodel Reports Second Quarter Fiscal Year 2014 Financial Results

May 12, 2014

Relypsa Announces Topline Results From Patiromer Phase 1 Onset-of-Action Study

May 12, 2014

SI-BONE, Inc. Announces Medicare Novitas Removes MIS SI Joint Fusion from Non-Coverage

May 9, 2014

Amarin Reports First Quarter 2014 Financial Results and Provides Update on Operations

May 8, 2014

NxStage Reports Record First Quarter 2014 Financial Results And Exceeds Guidance

May 8, 2014

Crown Bioscience Announces Research Collaboration with the National Resource Center for Mutant Mice (NRCMM)

May 8, 2014

Otonomy Completes Enrollment of AuriPro™ Pivotal Studies in Pediatric Patients Undergoing Ear Tube Placement Surgery

May 8, 2014

Response Biomedical Corp. Announces Voting Results

May 7, 2014

Relypsa Announces First Quarter 2014 Financial Results

May 7, 2014

Intercept Pharmaceuticals Reports First Quarter 2014 Financial Results

May 6, 2014

MacroGenics Provides Update on Corporate Progress and First Quarter 2014 Financial Results

May 6, 2014

Loxo Oncology Closes a $24 Million Series B Financing and Expands Management Team

May 6, 2014

Ambit Biosciences Announces First Quarter 2014 Operating Results

May 6, 2014

Intercept Reports Additional Positive OCA Data in Patients With Bile Acid Diarrhea at Digestive Disease Week

May 5, 2014

Aerpio Therapeutics Presents Full Results from Phase 1b/2a Study of AKB-9778

May 5, 2014

SAGE Therapeutics Appoints Thomas D. Anderson as Chief Commercial Strategy Officer

May 5, 2014

MacroGenics Presents Pre-Clinical Data on Inhibition of Autoimmune Diseases With DART Candidate MGD010 at IMMUNOLOGY 2014

May 2, 2014

Acutus Medical, Inc. Announces CE Mark for New 3D Diagnostic Imaging and Mapping Catheter

May 2, 2014

Amarin Announces Presentation of New MARINE and ANCHOR Post-Hoc Analyses at National Lipid Association Annual Scientific Sessions Showing Vascepa(R) Significantly Reduced Apolipoprotein C-III Levels

May 1, 2014

Loxo Oncology Initiates Phase 1 Trial of LOXO-101, a Selective Trk Inhibitor

May 1, 2014

SAGE Therapeutics Receives U.S. Orphan Drug Designation for Lead Compound SAGE-547 to Treat Status Epilepticus

Apr 30, 2014

RedHill Biopharma Reports Successful RHB-102 Bioavailability Clinical Trial and Planned Submission of European Marketing Application in Q3 2014

Apr 30, 2014

RedHill Biopharma Reports Results for the First Quarter of 2014

Apr 30, 2014

MacroGenics Appoints Atul Saran as Senior Vice President and General Counsel

Apr 30, 2014

Intercept Pharmaceuticals Appoints Rachel McMinn, Ph.D. as Chief Strategy Officer

Apr 30, 2014

Cleave Presents Poster at 2014 Cold Spring Harbor Meeting on Molecular Chaperones & Stress Responses

Apr 30, 2014

Otonomy Raises $49 Million in Oversubscribed Financing

Apr 28, 2014

Good Start Genetics Appoints Charles F. Wagner, Jr. to the Company’s Board of Directors - See more at: http://www.goodstartgenetics.com/about/news-coverage/#sthash.VBIBM0xF.dpuf

Apr 28, 2014

Practice Fusion Teams with Merck on Population Health Management Initiative

Apr 28, 2014

SI-BONE, Inc. Closes $33 Million Growth Capital Financing

Apr 28, 2014

RedHill Biopharma and IntelGenx Announce Commencement of a Bioavailability Study with RHB-103 (Migraine) to Support European Marketing Application Planned for Q3 2014

Apr 28, 2014

ALK enters collaboration to accelerate growth in China

Apr 24, 2014

RedHill Biopharma and IntelGenx Provide an Update on FDA’s Ongoing Review of the NDA for RHB-103 Oral Migraine Film

Apr 24, 2014

Sientra and RealSelf Announce Exclusive Initiative to Deliver New Education to Women Seeking Breast Augmentation

Apr 24, 2014

Durata Therapeutics Initiates Enrollment in a Phase 3b Study of Dalvance(TM) in a 1500 mg Single Dose

Apr 24, 2014

Crown Bioscience Enters Japanese Market via Strategic Partnership with Shin Nippon Biomedical Laboratories

Apr 23, 2014

ExcelPaces Approved by Management Board of Royal College of Physicians

Apr 23, 2014

Clementia Pharmaceuticals Marks Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day

Apr 23, 2014

Acceleron and Celgene Announce Interim Clinical Data for Sotatercept Demonstrating Dose Dependent Increases in Hemoglobin in Patients with End Stage Renal Disease on Hemodialysis

Apr 22, 2014

Crown Bioscience Passes 1000 Model Mark in PDX Collection for Oncology Drug Discovery

Apr 22, 2014

Biodel Announces Collaboration Agreement With HEC Pharm for Development of Ultra-Rapid-Acting Insulin Aspart Formulation

Apr 22, 2014

Principia Biopharma Secures $50 Million Series B Financing

Apr 22, 2014

Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology

Apr 21, 2014

ProNAi Therapeutics Raises $59.5 Million Series D Financing

Apr 19, 2014

InspireMD Announces First Patient Enrolled Into New CGuardTM CARENET (CARotid Embolic protection study using microNET) Clinical Trial

Apr 16, 2014

Relypsa, Inc. Announces Closing of Public Offering of Common Stock

Apr 14, 2014

Cerapedics Announces Closing Of Venture Debt Loan From GE Capital

Apr 12, 2014

Intercept Reports Additional Positive Data From POISE Trial at EASL Late-Breaker Session

Apr 10, 2014

BioLineRx Announces Investigator-Initiated Study for Novel Chronic Myeloid Leukemia Treatment

Apr 10, 2014

Affimed highlights further data on AFM13 at the 2014 AACR Annual Meeting

Apr 10, 2014

Relypsa, Inc. Announces Pricing of Public Offering of Common Stock

Apr 8, 2014

NxStage® to Report First Quarter 2014 Financial Results

Apr 8, 2014

Study Presented At Sages 2014 Shows Anterior Fundoplication With Medigus' Muse™ System Can Reduce Gerd Patients' Use Of Ppis

Apr 8, 2014

Relypsa, Inc. Announces Proposed Public Offering of Common Stock

Apr 8, 2014

Ambit Announces Initiation Of Quizartinib QUANTUM-R Phase 3 Trial

Apr 8, 2014

AlSubiya KIMS Expansions in Saudi Arabia

Apr 8, 2014

CardiAQ™ Valve Technologies Inc. (CardiAQ) appoints Paul Cornelison as Vice President of Regulatory Affairs, Quality Assurance & Clinical Affairs

Apr 7, 2014

Report: Practice Fusion Named the No. 1 Electronic Health Records (EHR) Vendor in Primary Care Practices for Fifth Year Running

Apr 7, 2014

Ambit Announces Initiation Of Phase 2 Cohort In MD Anderson Sponsored Study Of Quizartinib In AML And High Risk MDS

Apr 7, 2014

arGEN-X uses its SIMPLE Antibody™ platform to identify four ‘hotspots’ on MET as targets for its therapeutic antibody program

Apr 4, 2014

Data From Intercept's Pivotal Phase 3 POISE Trial of Its FXR Agonist Obeticholic Acid to Treat Primary Biliary Cirrhosis and Other Key Obeticholic Acid Data to be Presented at EASL 2014

Apr 3, 2014

Intercept Pharmaceuticals Announces Pricing of Public Offering

Apr 2, 2014

Relypsa Names Sylvia R. Wheeler V.P. Investor Relations and Corporate Affairs

Apr 1, 2014

SAGE Therapeutics Appoints Howard H. Pien to the Company’s Board of Directors

Apr 1, 2014

Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock

Mar 31, 2014

New Findings Highlight Good Start Genetics’ NGS Screening Capabilities in Ethnically Diverse Populations

Mar 31, 2014

Amarin and Kowa Pharmaceuticals America, Inc. Announce U.S. Co-Promotion Agreement for Vascepa(R) (icosapent ethyl) Capsules

Mar 31, 2014

Anthera Pharmaceuticals Announces Personnel Changes

Mar 31, 2014

FDA Advisory Committee Unanimously Recommends Approval of Dalvance(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Mar 31, 2014

Sony DADC and Singulex Announce Strategic Partnership for Proprietary Detection Vessels - See more at: http://www.singulex.com/singulex-press-releases/#sthash.CObq5IF4.dpuf

Mar 27, 2014

SAGE Therapeutics Initiates Phase 1/2 Trial of SAGE-547 in Status Epilepticus

Mar 27, 2014

PrimusLabs Strengthens Commitment to Food Safety Testing with Adoption of Roka Bioscience’s Atlas® System

Mar 26, 2014

Clementia Pharmacueticals Inc. Appoints Francois Nader, M.D. to Board of Directors

Mar 25, 2014

Anders Malm appointed Managing Director at Ecron Acunova GmbH, Germany

Mar 25, 2014

Singulex, in Partnership with Tecan, Commences Commercial Development of Ultrasensitive Sgx ClarityTM System for in vitro Diagnostics Market - See more at: http://www.singulex.com/singulex-press-releases/#sthash.CObq5IF4.dpuf

Mar 25, 2014

Roka Bioscience Atlas® Listeria monocytogenes LmG2 Detection Assay Expands Food Safety Testing Offering with Complete Solution for Listeria

Mar 24, 2014

Acceleron, Celgene and Collaborators Announce Two Publications in Nature Medicine Describing Sotatercept and ACE-536 Therapeutic Potential in Beta-thalassemia and Myelodysplastic Syndromes

Mar 24, 2014

Good Start Genetics Presents New Data Further Validating Clinical Value of GoodStart Select(tm) at PCRS Annual Meeting

Mar 24, 2014

Sonendo® Closes $10 Million Venture Debt Facility with Oxford Finance

Mar 24, 2014

Sonendo® Closes $10 Million Venture Debt Facility with Oxford Finance

Mar 22, 2014

Medigus Receives Fda Clearance For Next Generation Muse™ System

Mar 20, 2014

William R. Ringo Joins Mirati Board of Directors

Mar 20, 2014

Medigus Announces Study Validating Muse’S Safety And Efficacy In Gerd Patients To Be Presented At Sages 2014

Mar 19, 2014

Singulex’s Proprietary Ultrasensitive Research Test for Cardiac Troponin-I Predicts Coronary Heart Disease in the General

Mar 18, 2014

Igenica Biotherapeutics Enrolls First Patient in Phase 1 Study of IGN523 in Acute Myeloid Leukemia

Mar 17, 2014

BioLineRx Reports Year End 2013 Financial Results

Mar 17, 2014

Mirati Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results

Mar 17, 2014

Relypsa Announces Fourth Quarter and Full Year 2013 Financial Results

Mar 17, 2014

Good Start Genetics Announces Collaboration with PerkinElmer to Bring GoodStart Select ™ Carrier Screening Tests to Broader Women’s Health Market

Mar 17, 2014

Acceleron and Celgene Announce Interim Clinical Data for Sotatercept in Patients with End Stage Renal Disease on Hemodialysis at the 2014 National Kidney Foundation Spring Clinical Meeting

Mar 16, 2014

Intercept Announces Positive Pivotal Phase 3 POISE Trial Results

Mar 14, 2014

Durata Therapeutics, Inc. Reports Fourth Quarter and Full-Year 2013 Financial Results

Mar 14, 2014

BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 in Immunotherapy

Mar 14, 2014

Intercept Pharmaceuticals Announces 2013 Financial Results

Mar 13, 2014

Cleave is featured in Nature Biotechnology's academic spinouts of 2013

Mar 13, 2014

Response Biomedical Corp. Announces Fourth Quarter and Fiscal 2013 Financial Results

Mar 11, 2014

Cerapedics Announces Positive Results From IDE Clinical Trial

Mar 10, 2014

Alector Teams Up with Johnson & Johnson Innovation to Explore Novel Alzheimer’s Target

Mar 7, 2014

RedHill Biopharma Provides Update on RHB-102 Development and Intellectual Property

Mar 5, 2014

Biodel Announces Commercial Manufacturing Agreement With Emergent BioSolutions for Glucagon Rescue Product

Mar 4, 2014

Audentes Therapeutics Announces Significant Additions to Leadership Team

Mar 3, 2014

RedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film

Mar 3, 2014

BioLineRx Announces Underwritten Public Offering of its American Depositary Shares

Feb 28, 2014

Roka Bioscience Awarded AOAC-RI Certification For Atlas® STEC Eg2 Combo Detection Assay

Feb 27, 2014

Amarin Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Update on Operations

Feb 27, 2014

RedHill Biopharma and Salix Pharmaceuticals Announce Worldwide Exclusive License Agreement for RedHill’s RHB-106 Encapsulated Bowel Preparation

Feb 27, 2014

NxStage Reports Record Fourth Quarter and Full-Year 2013 Financial Results

Feb 26, 2014

InspireMD Reports Financial Results for the Quarter and Six Month Period Ended December 31, 2013

Feb 26, 2014

Acceleron Pharma Reports Fourth Quarter and Year Ended 2013 Financial Results

Feb 25, 2014

Cardioxyl Pharmaceuticals Initiates First Clinical Trial of CXL-1427

Feb 25, 2014

RedHill Biopharma Reports 2013 Fourth Quarter and Year-End Financial Results

Feb 25, 2014

Otonomy Appoints Robert Savel as Chief Technical Officer

Feb 24, 2014

PointClickCare and TigerText Bring Integrated Secure Text Messaging to Electronic Health Records

Feb 24, 2014

BioLineRx Appoints Dr. Sandra Panem to Board of Directors

Feb 21, 2014

Amarin Announces FDA Award of Three-Year Exclusivity for Vascepa(R) (icosapent ethyl) Capsules

Feb 19, 2014

Ornim Medical completes $10 million fundraising from OrbiMed Israel, with participation by GE and existing investors

Feb 18, 2014

Intercept Expands Its Board of Directors With Appointments of Sanj K. Patel and Glenn Sblendorio

Feb 13, 2014

Principia Biopharma Expands Executive Management Team

Feb 12, 2014

Ornim Medical Announces New Study Results Demonstrating the Value of the CerOx™ Cerebral Oxidation Monitor in the Treatment of Patients with Severe Traumatic Brain Injury

Feb 12, 2014

BioLineRx Announces Positive Preclinical Results for Novel Treatment for Chronic Myeloid Leukemia

Feb 11, 2014

Response Biomedical Corp. secures US$2.5 Million Term Loan

Feb 10, 2014

Pieris Achieves Preclinical Milestone Payment in Sanofi Collaboration

Feb 6, 2014

NxStage Medical Launches NxStage Plus One at 2014 Annual Dialysis Conference

Feb 6, 2014

Biodel Announces Plans to Advance BIOD-531 Based on Positive Clinical Trial Results

Feb 5, 2014

Audentes Therapeutics and Genethon Announce Agreement to Develop Treatment for Severe Genetic Disease X-Linked Myotubular Myopathy

Feb 5, 2014

InspireMD Reports Successful Implantation of the New CGuardTM Carotid Embolic System with MicroNetTM Technology

Feb 5, 2014

Report: Practice Fusion Nabs Top Spot as the Largest Cloud-Based EHR in the U.S.

Feb 5, 2014

TigerText Hires Former Symantec and LinkedIn Leaders to Build Out Engineering and Product Teams

Feb 5, 2014

ViewRay Announces World's First Patients Treated Using MRI-Guided Radiation Therapy

Feb 4, 2014

Roka Bioscience Awarded AOAC-RI Certification For Atlas® E. coli O157:H7 EG2 Detection Assay

Feb 4, 2014

Amarin Announces Promotion of Aaron Berg to Senior Vice President, Marketing and Sales

Feb 4, 2014

Relypsa Completes Enrollment of Phase 1 Onset-of-Action Study for Patiromer

Feb 4, 2014

RedHill Biopharma and IntelGenx Receive Complete Response Letter from FDA for RHB-103 Oral Film for Acute Migraines

Jan 29, 2014

Clementia Pharmaceuticals Inc. Announces Key Leadership Appointments

Jan 28, 2014

Acceleron Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 28, 2014

Igenica Raises $14 Million in Additional Series C Funding to Advance Product Pipeline and Technology Platform

Jan 27, 2014

TigerText Caps Record Year with $21 Million Series B Investment to Accelerate Market Penetration

Jan 27, 2014

Ambit Biosciences Appoints Mark Foletta To Board Of Directors

Jan 24, 2014

Medigus Unveils Commercial Strategy and New Branding for the MUSE™ System

Jan 23, 2014

BioLineRx Receives Orphan Drug Designation for Novel Stem Cell Mobilization Treatment

Jan 22, 2014

RedHill Biopharma Closes Previously Announced $11.7 Million Private Placement

Jan 21, 2014

Amarin Announces FDA Review Division Response to ANCHOR SPA Agreement Reinstatement Request

Jan 13, 2014

Lilly Announces Acquisition of CGRP Antibody for Migraine Prevention from Arteaus Therapeutics

Jan 13, 2014

arGEN-X starts Phase Ib expansion cohorts with ARGX-110, a novel anti-CD70 antibody, in cancer patients

Jan 13, 2014

arGEN-X receives two preclinical milestone payments under collaboration with Shire

Jan 13, 2014

Relypsa Provides Corporate Update

Jan 13, 2014

BioLineRx Announces Regulatory Submission for Novel Stem Cell Mobilization Treatment

Jan 9, 2014

Adimab Announces New Partnerships with Jounce, Five Prime, and Alector

Jan 9, 2014

RedHill Biopharma Announces Closing of $8.5 Million Private Placements from OrbiMed and Broadfin

Jan 9, 2014

Intercept Announces NASH Primary Endpoint Met: FLINT Trial Stopped Early for Efficacy Based on Highly Statistically Significant Improvement in Liver Histology

Jan 9, 2014

CLEMENTIA PHARMACEUTICALS INC. ANNOUNCES CLOSING OF $22.5 MILLION SERIES A FINANCING WITH PREEMINENT U.S. AND CANADIAN HEALTHCARE VENTURE CAPITAL FUNDS

Jan 8, 2014

BioLineRx and JHL Biotech to Collaborate on Type 1 Diabetes Antibody Treatment

Jan 6, 2014

Eddingpharm Acquired Global Rights to Oncology Assets, Including Telatinib, from ACT Biotech

Jan 2, 2014

Cerenis Reports Top-Line Phase II Results for its HDL Mimetic CER-001
Watch OrbiMed Advisors' Managing Partner, Sam Isaly on CNBC US

March 7, 2017

Watch OrbiMed Advisors' Managing Partner, Sam Isaly on CNBC US.

Our professional values trump net present values any day. OrbiMed is a collegial culture, working together for over 25 years in a collaborative, diverse, team-oriented environment.